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ABSTRACT OF DISSERTATION

TARGETED POLYMERIC BIOMATERIALS FOR THE PREVENTION OF POST
SURGICAL ADHESIONS
Despite recent advances in surgical technique and the development of numerous
therapeutic agents, the formation post surgical adhesions (PSA) continues to cause
complications for many patients. In this research, we have employed a rational system to
develop a novel treatment to address this clinical need. Based on an understanding of the
biochemical events that lead to PSA formation, a series of targeted polymeric
biomaterials was designed to interrupt the fibrin gel matrix propagation and suppress
PSA formation.
Using group transfer polymerization, a series of well controlled block copolymers
of polyacrylic acid and poly(ethylene glycol-methacrylate) based materials was
synthesized. Subsequent functionalization with the pentapeptide Cys-Arg-Glu-Lys-Ala
(CREKA) was employed to target the materials to fibrin as a marker of pro-adhesive
sites. While preliminary testing of the untargeted materials verified their ability to
suppress non-specific protein adsorption to model surfaces, numerous in vitro tests were
conducted to study the ability to inhibit fibrin gel propagation. The ability to inhibit both
the rate and quantity of fibrinogen deposition to a fibrin coated surface has been
demonstrated. In addition, the rate of fibrin gel propagation and the degree of cellular
attachment can modulated.
Taking advantage of the systematic variation in structure facilitated by the robust
synthetic methodology employed, statistical analysis was used to elucidate the structureproperty relationships governing the performance of these materials. The most important
factors that lead to enhanced performance in in vitro tests are the length of PEG chain and
number of peptide units conjugated to the polymer: increasing PEG chain length and
increasing the number of peptides conjugated to the polymer both improve performance
in all tests. The synthetic methods that have been developed, in conjunction with the
experimental results, will be used to direct future studies, including cytotoxicity and
animal studies.
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CHAPTER 1. INTRODUCTION

Post-surgical adhesions (PSA), abnormal fibrous linkages between adjacent tissue
surfaces, represent one of the most common and significant complications facing surgical
recovery today. It is believed that the vast majority of surgical patients experience this
complication [1-2]. While, in most cases, these adhesions are not problematic, many
patients require subsequent treatment(s) to correct the complications that arise.
Approximately 440,000 adhesiolysis procedures are performed each year in the United
States at an estimated total cost of over $1 billion [3-4]. Numerous strategies have been
investigated to reduce adhesion formation, including changes in surgical technique and
the development of adhesion barrier strategies. Unfortunately, no method has yet been
devised that provides general applicability and affords adequate protection.
In this research, we have developed a new targeted polymeric material designed
to address this problem by assembling at pro-adhesive sites and providing protection
against PSA formation. The preliminary data contained herein suggest that this material
may provide a novel approach to the prevention of post surgical adhesions. In vitro
studies have demonstrated the ability of these synthetic polymeric materials to assemble
onto model surfaces and prevent the early steps (e.g., protein absorption, fibrin growth,
cellular attachment) in the event cascade that leads to PSA formation.
A rational design approach was used to identify the molecular properties that can
be used to engineer a potential treatment to meet a specific medical condition. Based on
the physiology and pathology of post surgical adhesion formation, polymeric materials
were designed to interact with the fibrin gel matrix and suppress its development. These
polymers incorporated peptide targeting units to control the interactions with fibrin and
1

polyethylene glycol units to form a surface layer that resists subsequent fibrin deposition.
Preliminary testing demonstrated the viability of the concept, while more thorough
experiments confirmed the ability to modulate the series of biochemical events that lead
to adhesion formation. As anticipated, the structure of the polymer employed exerts
dramatic influence on the ability of these materials to function as designed. Based on the
encouraging results obtained from these experiments, in vivo studies are planned to assess
the function of these materials in a rabbit model.

Copyright © John M. Medley 2010
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CHAPTER 2. BACKGROUND

Based on review published in:
Biological Interactions on Materials Surfaces Understanding and
Controlling Protein, Cell, and Tissue Responses Puleo, David A.; Bizios,
Rena (Eds.) 2009 [5]. Used with permission.

2.1.

Problem Statement
Each year in the United States, millions of people submit themselves to

abdominal surgery for a variety of reasons, including gynecological reconstruction, tumor
removal, and Cesarean sections [1-2]. While the success rate and recovery times for the
initial surgeries are continually improving, complications frequently occur. One major
complication of abdominal surgery, occurring in the vast majority of patients, is the
formation of tissue adhesion. While it is impossible to determine the incidence rate with
certainty, several studies indicate that post surgical adhesion formation occurs in 65 –
97% of abdominal surgery patients [1-4]. This acellular, collagen rich tissue often forms
when an organ is damaged due to inadvertent desiccation or trauma during surgery.
During healing, this damaged tissue often becomes permanently attached to adjacent
tissues by the formation of a fibrous scar, as shown in Figure 2-1. While the nearly
ubiquitous formation of adhesions is not generally problematic, numerous problems can
arise that require subsequent physician care. Many patients experience abdominal or
pelvic pain, intestinal obstructions, infertility, and increased difficulty in subsequent
surgical procedures. In addition to the immeasurable costs in patient pain and suffering,
an estimated 440,000 adhesiolysis procedures are performed in the United States each
year [3-4].
3

2.2.

Post-surgical Adhesion (PSA) Formation
The mechanism of these formations has been shown to follow the same basic

pathway as intraperitoneal wound healing. The cells, proteins, and tissues involved in this
mechanism, which have been described in numerous review articles, are shown
graphically in Figure 2-2 and can be summarized as a sequence of eight steps, as
described in Table 2-1 [6-8]. When this process initiates on an open surface, typical
wound healing is observed, including the associated scar tissue formation. If an opposing
surface is bridged by the Fibrin Gel Matrix (FGM) (see Table 2-1, step 6), the resulting
scar tissue can permanently connect these surfaces, resulting in the formation of post
surgical adhesions.
Depending where these adhesions form, a variety of complications are possible. If
the adhesions involve the intestines, bowel obstructions can result [9-11]. In female
patients, adhesions can obstruct the fallopian tubes and result in reduced fertility [9, 1213]. Following surgery, many patients experience abdominal pain, which is believed to
be a result of reduced mobility of the organs within the abdominal cavity [9, 12, 14-15].
Finally, subsequent surgeries can be complicated as tissue adhesions may interfere with
the surgeon’s access to organs [16-17]. Adhesions also form in areas of the body outside
of the abdominal cavity. Numerous medical specialties, including cardiosurgery,
neurosurgery, and orthopedic surgery, are plagued by the formation of complications
arising due to postsurgical adhesion [18-23].
The costs associated with PSA in the United States are substantial. Approximately
300,000 hospital readmissions annually are either directly or indirectly related to the
formation of PSA; the annual financial expenditure for pertinent treatment costs exceeds

4

$1.3 billion [3, 8]. Based on the significant financial costs and the immeasurable cost in
terms of patient discomfort, the need either to eliminate or reduce the incidence and
severity of PSA is apparent.
2.3.

Methods of PSA Prevention and Control
Based on the well-characterized PSA formation mechanism, researchers and

physicians have developed numerous approaches to prevent their formation. These
approaches can be classified into four general categories: modification of surgical
technique, pharmaceutical approaches, liquid instillates, and adhesion barriers. While
none of these techniques can eliminate the incidence of PSA completely, each approach
has demonstrated encouraging results, with research continuing along all four directions.
2.3.1. Modification of Surgical Technique
Since PSAs are known to form as the result of tissue trauma, it is logical that the
number and severity of PSA can be reduced by reducing the trauma to tissues during
surgery. Simple changes, such as implementing the use of non-powdered surgical gloves,
can reduce desiccation of the peritoneum and have a positive impact. During open
abdominal surgery, the peritoneum is often sutured closed to aid healing. This practice
increases the length of surgery and, since the peritoneum is known to heal rapidly via
island implantation, it has recently been questioned [24-26]. Several studies have recently
been conducted to assess the necessity of suturing the peritoneum and its affect on the
formation of PSA; the results have been mixed [1-2, 13, 24-26]. As described in Section
2.5, the presence of suture materials can induce an exacerbated wound healing response,
due to the foreign body reaction, and promote PSA formation [27].

5

Another common surgical procedure, installation of prophylactic drainage tubes
following abdominal surgeries, has also been a subject of investigation [28]. Often
performed as an effort either to remove excess serum and blood (to reduce infection) or
to provide an early warning of surgical complications, the necessity of this technique is
uncertain [29-32]. In fact, the presence of drainage tubes can increase the likelihood of
infection following abdominal surgery and has been shown to increase the incidence of
PSA [31].
Recent investigations suggest that increasing the oxygenation of tissues in the
abdominal cavity may affect the biochemistry of the wound healing process. Reduced
oxygen levels in tissue (e.g., due decreased blood flow) can reduce the ratio of tissue
plasminogen activator (tPA) to plasminogen activator inhibitor-1 (PAI-1) present in that
tissue [33]. Since plasmin is necessary to break down the fibrin gel matrix (see Table
2-1, step 6), this reduced oxygen level may contribute to increased PSA formation.
Oxygenating tissues during surgery has demonstrated some success at reducing the
impact of PSA [33].
Since PSA is a result of trauma to the internal organ surfaces, reductions in the
incision size, shortening the time of surgery and the overall invasiveness of the procedure
should result in a reduction of PSA. Indeed, laparoscopic surgical methods have resulted
in a major reduction in the incidence and severity of PSA [34-36]. Unfortunately, not all
surgeries, such as gynecological reconstruction or emergency procedures, are amendable
to laparoscopic methods. In addition, even though the incidence of PSA is reduced,
laparoscopy can result in some tissue trauma with PSA formation still a likely outcome.
Implementation of improved surgical procedures, while effective at reducing the

6

incidence and severity of adhesions, does not eliminate the risk of PSA formation. A
significant clinical need still exists for alternative interventions to inhibit PSA formation.
2.3.2. Pharmaceutical Interventions
Since PSA formation is a product of uncontrolled wound healing, by
pharmacologically intervening in this process, it may be possible to reduce the effect of
pathways leading to tissue adhesions. However, implementation of these techniques has
been frustrated by the complex biochemical nature of the wound healing process. For
example, while it may be desirable to modify the healing process at the site of basement
membrane exposure, biological approaches can potentially disrupt the beneficial healing
throughout the body, resulting in more severe post-surgical complications.
Initial attempts to employ pharmaceutical agents focused on the reduction of
tissue trauma. Local application of anti-inflammatory medications (i.e., ibuprofen,
steroids, antihistamines, etc.) has been used to reduce inflammation at the surgical site.
Interestingly, these therapies have demonstrated some efficacy during preclinical trials at
reducing the formation of PSA [37-38]. This result is likely due to the understood link
between excessive inflammation and fibrosis [39].
Similarly, attempts at mitigating oxidative stress at the wound site have also been
employed to suppress the formation of PSA.

While generation of oxygen radicals

(typically from the leukocyte respiratory burst) [40-41] is a necessary part of the wound
healing cascade, an excessive amount is known to activate collagen producing cells
resulting in exaggerated levels of fibrosis [42-43]. It is logical to expect, then, that
administration of antioxidant molecules would suppress formation of collagen rich tissues

7

[44]. Melatonin, vitamin E, and catalase have all shown some promise in reducing the
severity of post surgical adhesion formation [44-47].
Heparin, a naturally occurring anticoagulant, interrupts various steps of the
coagulation cascade and inactivates thrombin. Used to treat numerous pathologies and to
create biologically-passivated surfaces, heparin has been investigated as an agent to
reduce PSA formation. The results of these investigations, however, have been
disappointing [48].
The most beneficial pharmaceutical interventions have employed fibrinolytic
agents to reduce PSA formation. These enzymes, occurring naturally in the body, play a
key role in the degradation of blood clots. As a result of trauma caused by surgery,
production of these enzymes is suppressed [49-50]. It was proposed that the formation of
PSA can be prevented by accelerating the degradation of fibrin deposits with locally
delivered fibrinolytic agents to break down the fibrin gel matrix (FGM). This adhesive
fibrin gel matrix is responsible for the formation of the initial deleterious union of
adjacent tissue surfaces. Early investigations involved treatment with bacterially-derived
streptokinase, a protein that catalyzes formation of plasmin which, in turn, breaks down
the fibrin mesh of blood clots [51]. Increased plasmin activation proved beneficial in both
animals and in humans and resulted in the commercialization of “Varidase” in the 1970s
[52-54]. Additional investigations used the plasminogen activator enzyme, urokinase, and
plasmin directly via intraperitoneal injection; mixed results and potentially immunogenic
responses were observed [55-56]. Despite these inconsistencies, direct management of
fibrin, the primary adhesive protein, represents an attractive PSA prevention strategy.
Recent studies, focusing on the use of recombinant tissue plasminogen activator (rt-PA)
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demonstrated significant potential to successfully address PSA formation [50]. While the
use of tissue plasminogen activators has shown efficacy in reducing the incidence of PSA
formation, they have been shown to increase the risk of hemorrhage in many applications
[2, 57-58].
Oral delivery of drugs to reduce PSA formation has recently been investigated
[59]. Chymases, naturally occurring proteases, stimulate accumulation of neutrophils and
other inflammatory cells at the trauma site; these enzymes cleave procollagen into
collagen fibrils, a primary step in the formation of the collagen rich tissue bridge. It was
hypothesized that, by inhibiting/slowing the formation of collagen fibrils, the FGM could
break down before PSA formation can occur. A recent study employed oral delivery of
NK3201, a novel chymase inhibitor, showed significant reduction in chymase activity
and, thereby, suppressed PSA formation in a hamster model [59].
2.3.3. Liquid Instillates
During surgery, saline solution is typically instilled into the body cavity to
accomplish a number of goals. In addition to maintaining a clean surgical site (by
removing blood and other biological debris), this solution also maintains hydration of
exposed tissues. In an effort to reduce PSA formation, several alternate liquid instillates
have been investigated.
Hyaluronic acid (HA), whose chemical structure is shown in Table 2-2, is a
naturally-occurring biological polymer consisting of a long chain of disaccharide units
with a molecular weight that can exceed 20 million Daltons. HA is a principal component
of the extracellular matrix of tissues throughout the human body. HA can readily be
broken down into its principle sugar molecules and metabolized within the body; these
9

degradation units, both monomeric and oligomeric, are potent signals for macrophage
and cell recruitment, angiogenesis, and the presumed non-scarring, fetal-like, wound
healing response [60-63]. Because of these properties, the use of HA has been
investigated as a means to reduce PSA formation. If instilled prior to surgery, HA can
effectively coat the organs in the abdominal cavity and provide protection against
surgical trauma and tissue desiccation [64-65]. HA reduces the tissue adhesion score to
0.9 ± 1.1 versus 2.0 ± 0.8 obtained from the controls in a mouse model and has been
approved for use by the FDA [64].
Several chemical modifications of HA have been formulated in order to improve
its in vivo performance. By slowing HA degradation kinetics, it is believed that additional
protection against PSA formation can be obtained. HA crosslinked with ferric ion
(FeHA) reduced adhesion scores by 59% in clinical trials and led to the commercial
product “Intergel” [66-67]. This product was withdrawn from the market after reports of
additional complications, including pain and a foreign-body response attributed to the
high iron content [48, 68]. By esterifying the hydroxyl groups on one HA chain with the
carboxyl groups on another HA chain, it is possible to form an autocrosslinked HA
derivative (HAx). This material forms a hydrogel and provides surface tissue protection
for a longer duration. Tests in a rabbit model demonstrated the reduction in the adhesion
score from 3.0 for controls to 0.5 in the treatment groups [69]. Clinical trials have also
demonstrated reductions in adhesion scores of approximately 60% versus controls [7071]. In addition, it is not clear whether these esterfied HA monomers possess the same
degree of chemotacticity as native HA and, thereby, alter the rate of cellular infiltration
and wound healing at the surgery site [72].
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The most effective HA-derived liquid instillate employs crosslinked HA with
another biologically-derived polymer, carboxymethylcellulose (CMC). CMC, whose
structure is shown in Table 2-2, is a non-toxic material, used as a thickening agent in
many food and drug products. CMC is not degraded in the body as rapidly as HA [69, 7374]. After partial oxidation, HA can be chemically crosslinked with CMC; this chemical
combination of HA with CMC, which is commercially available as “Sepracoat,” results
in an instillate with a residence time in the abdominal cavity of approximately seven days
[66, 75-77]. This material has demonstrated significant protection against PSA formation
in animal models but failed to convince the Federal Food and Drug Agency Panel of its
clinical effectiveness against preventing adhesions in human patients [78].
Liquid instillates based on the chemistry of phospholipids have also been
employed. These materials, whose general chemical structure is shown in Table 2-2, are
amphiphilic: they have a polar, hydrophilic head group and a hydrophobic tail. This
amphiphilicity accounts for the surfactant properties exhibited by these materials; they
adhere to hydrophilic surfaces and form a protective boundary lubricating layer with their
hydrophobic tails extending from the surface [79]. Several amphiphilic lipids
(phospholipids, sphingolipids, galactolipids), have been tested to reduce PSA formation
and demonstrated significant potential to reduce PSA formation [80-82]. In a rabbit
model, these materials reduced the area of adhesion formation from 691 mm2 to 191 mm2
[80].
Another class of materials has been designed to provide protection in the
abdominal cavity without pretreatment via hydroflotation. The saline solutions typically
used for irrigation during surgical procedures fall into this category. “Adept,” a
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commercial product based on icodextrin, a polymeric starch, whose chemical structure is
shown in Table 2-2, has been used for irrigation and rinsing during surgery [83]. After
surgery, the polymeric starch is absorbed into the lymphatic system very slowly due to its
high molecular weight [84]. Because of its high concentration, this material increases the
osmotic pressure in the abdominal cavity and maintains an increased level of fluid [85].
The presence of this excess fluid results in tissue separation and has been shown to
decrease PSA formation [84, 86-89]. In the rabbit dual uterine horn model, “Adept”
increased the number of adhesion-free sites to 50% versus the 5% obtained for the
untreated controls [84].
Polyethylene glycol (PEG), discussed in Section 2.5, has also been employed in
efforts to reduce PSA formation. This material, often referred to as polyethylene oxide
(PEO), was proven biocompatible in a number of applications and is under investigation
for a number of additional uses [90]. PEG, whose chemical structure is shown in Table
2-2, consists of a series of repeating ether units with either hydroxyl or methoxy
terminations at both ends.

This structure renders PEG amphiphilic and resistant to

protein adsorption. Soluble in many organic solvents, PEG is highly hydrophilic and can
form a hydrated layer with a large excluded volume and high steric stabilization [90-91].
PEG surfaces present few binding sites for protein interactions; for this reason,
adsorption of proteins, and subsequent adhesion of cells, is strongly inhibited. Injection
of PEG into the peritoneal cavity has been moderately successful in preventing PSA
formation [4]. Yet, because of their anti-adhesive nature, free PEG chains adhere poorly
to surfaces. Attempts to increase the protective ability of PEG by crosslinking with CMC
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into a viscous gel have achieved a 42% reduction in the American Fertility Society
adhesion score versus the relevant controls [92].
A recent attempt to prevent PSA formation employed sequential use of solutions
containing charged polypeptides [93]. A solution containing poly(L-lysine) (PLL) was
instilled into the peritoneal cavity followed by a solution of poly(L-glutamate) (PLG) five
minutes later. Positively-charged PLL, whose chemical structure is shown in Table 2-2,
adheres to damaged tissues. Negatively-charged PLG, whose chemical structure is also
shown in Table 2-2, associated with the positively-charged PLL on the surface and forms
an insoluble film at the site of injury. In animal studies employing a mouse model, this
system reduced the incidence of PSAs from 49.5% in the animals to 8.81% in treated
animals [93-94]. Further implementation of these materials may be hampered because of
toxicity concerns associated with the highly charged polyamines employed [93].
2.3.4. Adhesion Barriers
Currently, the most consistently effective methods that reduce the incidence and
severity of PSA formation provide physical separation of wounded from surrounding
tissues. By isolating damaged or potentially damaged surfaces from each other during the
wound healing process, normal healing without the formation of PSAs was achieved [2,
8]. Because of the simplicity and efficacy of this approach, numerous barrier systems
have been investigated.
The first adhesion barrier system investigated consisted of grafts of peritoneal
tissue aimed at providing protection to areas of damaged peritoneum. The presence of
necrotic graft material, however, promoted, rather than inhibited, PSA formation in
animal trials [48]. Other attempts to protect tissues by stretching the nearby peritoneal
13

membrane also proved ineffective [48]. Decreased blood flow in this distorted tissue
results in decreased plasmin activation and enhanced the formation of the fibrin gel
matrix [48].
Another material that has been investigated for use as an adhesion barrier is
poly(tetrafluoroethylene) (PTFE) [95]. Because PTFE is known to resist adhesion to most
substances, it is a natural candidate for use as a PSA barrier. This material, whose
structure is shown in Table 2-2, consists of a straight chain of carbon atoms onto which
fluorine atoms are fully substituted. The fluorine atoms present an inert, electron-rich
surface that prevents strong interactions with other materials. PTFE is readily available as
an expanded mesh, commonly referred to as ePTFE, under the trade name “Gore-Tex
Surgical Membrane” [96-97]. The presence of PFTE between damaged tissue surfaces
prevents the FGM from bridging these tissues and, thus, prevents PSA formation [3, 98101]. In animal tests employing a porcine model, PTFE reduced the adhesion score to
0.14 ± 0.12 versus the observed 1.33 ± 0.41 for controls [101].
The major drawbacks of PTFE result from its high degree of inertness. Since
PTFE is so effective at preventing interactions with biological tissues, it typically must be
sutured into place in the body [102]. In addition, PTFE is not biodegradable. Ideal for
permanent prosthetic applications, the use of PTFE as an adhesion barrier can be
problematic [99]. After the body has healed from the trauma induced by surgery,
typically within about two weeks, the presence of the PTFE membrane at the site of
trauma is undesirable. A second surgery, then, is typically necessary to remove this
barrier material and ensure that unwanted complications are prevented [100].
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Several barrier membranes have been investigated that overcome this limitation of
PTFE. Designed to be readily biodegradable, such membranes often do not need suturing
into position and, thus, subsequent removal. After the desired protection has been
rendered, these membranes break down and are metabolized by the body. Numerous
biodegradable materials have been investigated for use as adhesion barriers, including
cellulose derivatives, hyaluronic acid derivatives, and PEG-based materials [102-107].
Oxidized regenerated cellulose (ORC) was employed to form a barrier that was
successfully commercialized under the trade name “Interceed.” Cellulose, a naturally
occurring polysaccharide, whose structure is shown in Table 2-2, is partially oxidized to
improve aqueous solubility. This biodegradable material has a gauze-like consistency and
can be applied directly to damaged tissues in order to prevent PSA. When properly
applied, this material has shown a high degree of efficacy in reducing PSA formation in
surgical procedures. There are, however, several limitations to the clinical use of
“Interceed” [94, 99]. Because it is thrombogenic, contact with blood greatly increases the
likelihood of subsequent surrounding tissue adhesion; because of this property, complete
hemostasis must be achieved prior to in situ application of “Interceed.” In addition,
application must be limited to a single layer of material in all areas; multiple layers may
promote adhesions [48]. These difficult handling requirements render “Interceed”
unsuitable for laparoscopic procedures and limit its general applicability to more invasive
laparotomic procedures.
Barriers based on HA crosslinked with CMC are available under the trade name
“Seprafilm.” This material is applied as rigid sheets that, once hydrated, form a protective
gel on the abdominal tissue surface and prevent PSA formation. With a chemical
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composition nearly identical to “Sepragel,” this material is readily biodegraded in vivo
within about one week. Provided that a surgeon has knowledge and access to all areas of
tissue damage, “Seprafilm” can be very effective at preventing PSA formation [102-104].
In animal studies employing a rat model, the total adhesion score was reduced to 4.15 ±
0.58 from 7.21 ± 0.52 obtained for the respective controls [77]. A meta-analysis of
clinical data also demonstrated “Seprafilm” to be effective at lowering the incidence of
PSAs in abdominal surgeries [108]. While this study mistakenly included a non“Sepracoat” HA/CMC material in its analysis, it reported that patients receiving the
“Sepracoat” were 8.71-times more likely (p < 0.01) to have no adhesions than the control
group (p < 0.01) [108]. While the rigid structure of “Seprafilm” has traditionally
prevented its use in laparoscopic surgery, newer techniques involving the use of rolled
films has provided some limited laparoscopic use [109].
Since the number of procedures performed by laparoscopic surgery is continually
increasing, the ability to apply antiadhesive therapies via this method is increasingly
important. A material recently developed to address this clinical need is the twocomponent system commercially available as “SprayGel.” This system consists of a
double-barrel syringe used to apply the contents to damaged tissue via laparoscopy. Each
barrel contains a reactive PEG precursor solution. Upon mixing, an amine group from
one component reacts with N-hydroxysuccinimide (NHS) ester in the other component to
form a crosslinked hydrogel, as shown in Table 2-2. This crosslinked material degrades
in vivo into PEG units that are rapidly removed from the body by renal clearance [105106]. Since “SprayGel” is readily applicable in laparoscopic procedures, the major
limitation for its use in PSA suppression is the surgeon’s awareness of, and access to,
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damaged tissues. In clinical trials, this material showed significant efficacy because it
reduced the mean adhesion tenacity score by 64.7% versus the values obtained for the
untreated controls [110].
The aforementioned adhesion barriers have proven efficacious in reducing PSA
formation in patients; for this reason, these commercially available products are enjoying
success in the marketplace. Even with these methods, however, PSA formation is still
occurring. For instance, in the 2007 meta-analysis of “Seprafilm” described earlier, of the
371 patients in the adhesion barrier treatment group (combined over several studies), 196
still had developed a post surgical adhesion [108]. With a prevention rate of only ~ 48%,
multiple hypotheses have emerged to explain the persistent occurrence of PSA. If the
surgeon is unaware of damaged tissue or if the damaged site is inaccessible, current
barrier methods may not be effective and tissue adhesion formation remains a likely
outcome. To overcome these deficiencies, many new strategies for the prevention of PSA
are currently being investigated. Some of these investigations focus on combinations of
techniques that have demonstrated success in the past. For example, various hydrogels
have been loaded with either anti-inflammatory, antibiotic, or fibrinolytic agents,
including budesonide, paclitaxel, or streptokinase [38, 46, 111-113]. In addition, changes
to pertinent surgical technique are under investigation [31, 33, 59]. A brief summary of
the most widely investigated PSA prevention methods is given in Table 2-3.
2.4.

PSA Evaluation Methods
Perhaps one of the biggest impediments to the rapid development of PSA

prevention strategies, especially to the testing of barrier materials, is the lack of a
standard and widely used method to evaluate and compare pertinent performance. The
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situation is complicated because various animal models are used and each clinical trial is
conducted independently. Due to the complex interplay of the many facets of the wound
healing process, inflammatory cascades, and anatomical aspects, in vivo studies are an
integral part of PSA evaluation. Animal testing, however, is, by its nature, very complex,
time consuming and limited in its ability to provide useful data comparisons among
studies. In addition, large-scale screening of materials is not typically possible because of
the associated high cost, time requirements, and ethical issues. Furthermore, in most
animal models, failure of PSA treatment strategy does not always provide useful
information regarding the underlying mechanism of failure. Methods of assessment have
been primarily based on semi-quantitative animal models, including mouse, rat uterine
horn, rabbit, and porcine; these models are summarized in Table 2-4. The results of such
studies are typically scored based on visual observations (e.g., no adhesion, filmy
avascular adhesion, vascularized adhesion, collagen rich adhesion) in an attempt to
provide meaningful comparisons. Because of the large variability in the test methods and
in data analysis, it is generally not possible to conduct meaningful comparisons between
independent investigations. Results of material performance are often either confounded
or obscured by the differences in the models and scoring systems employed.
Furthermore, there has been a significant lack of translational relevance from in
vivo PSA treatment models to clinical application and success. A strong need exists to
revisit the fundamental aspects of adhesion formation and obtain more information
regarding the underlying mechanisms for both the success and failure of each treatment.
Recent attempts to address these issues have focused on standardizing the methods of
testing and quantifying tissue adhesion formation. A grading system, described in Table
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2-5, was developed to evaluate three characteristics (specifically, extent, severity, and
degree) of adhesion formation; application of these three measures assigns a total
adhesion score [114]. While still semi-quantitative, this grading system provides some
quantitative information and allows comparisons to be made between the results of
various studies.
Most recently, complete quantitative investigations and in vitro models are being
developed to allow for a rational optimization of potential treatments prior to large-scale
animal tests. Investigators have reported preliminary results indicating that tissue
adhesions can be reproducibly formed in a porcine model and analyzed using a tensile
test system [115]. This tensile strength analysis method provides bulk modulus data of
the formed scar tissue, allowing direct quantitative assessment of the quality and maturity
of the adhesion and does not rely upon physical appearance alone [115].
In order to overcome many of these limitations, a comprehensive understanding
of the nature of the mechanism controlling the PSA reduction is highly desirable. This
result can be achieved by developing reproducible in vitro tests and systematically
studying the effects of various materials on the results. If this work can then be correlated
with the results of in vivo studies, the relative importance of various in vitro tests can be
assessed and development of additional PSA prevention strategies can be carried out in a
much more systematic and efficient manner.
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2.5.

Biomaterials

2.5.1. Background
Over the past three decades, the medical field has benefitted greatly from
numerous advances in material properties. Since the early 1980s, several definitions have
been proposed to describe the field of biomaterials [116-118]. The main concepts that are
generally regarded as important in designing a biomaterial are that something interact
with the body in a desired manner and that it provide the desired function. One widely
used definition of a biomaterial was promulgated in 1987: “A biomaterial is a nonviable
material used in a medical device, intended to interact with biological systems” [119].
This broad field of study encompasses a wide array of materials and devices, ranging
from simple disposable catheters and syringes to complex, permanently implanted
devices such as artificial joints and pacemakers. Recent advances have enabled the
development of increasingly complex biomaterial devices, such as those used for tissue
engineering and artificial organs [118, 120-121]. As these devices have become more
complex and permanent, understanding and controlling the interactions of the component
materials with the body has become increasingly important.
2.5.2. Biomaterial Interactions
Consisting principally of cells, proteins, and extracellular matrix, natural tissue is
a complex, active material. Each component contributes unique functionality to the
tissue, and the synergistic effect of these components creates a sophisticated composite
system.

Conversely, typical synthetic biomedical implants consist of much more

homogeneous materials that have been optimized for a particular function. As a result,

20

implant materials are often inferior to natural tissues in many ways, including strength,
elasticity, and capacity for self-repair.
Another difficulty with biomaterials is that implants are rarely constructed from
materials native to the patient. When a biomaterial is implanted into the body, a complex
series of biochemical events is triggered. Initially, the body’s response is focused on
hemostasis. During the ensuing inflammatory phase, the body attempts to isolate or
remove any injurious agents using its natural defenses. Depending on the nature of the
biomaterial, this inflammation typically relies on the action of macrophages and is of
relatively short (less than one week) duration. If inflammation persists for more than
approximately 1 week, chronic inflammation, characterized by the presence of monocytes
in the affected area, may result. Over time, these monocytes may differentiate into
macrophages and lead to the formation of foreign body giant cells. [7-9, 122-126].
In the absence of chronic inflammation, the repair and remodeling phase of
healing continues and the implant site is stabilized. The implant is incorporated into a
collagenous fibrous capsule. The nature of this capsule is dictated by both the
composition and structure of the implant material and by the location of the implant [125,
127-129]. For non-toxic, non-degradable materials, minimal fibrosis may be observed
[130-131]. If implants are composed of more reactive materials, the resulting
encapsulation becomes more extensive and consists primarily of collagen with some
fibroblasts and macrophages [125, 131]. Materials that elicit a strong foreign body
response result in the formation of a thick, fibrous capsule formation and may impede
integration of the implant with native tissue. Finally, if a more pronounced
incompatibility is seen, a more significant immunological response may be induced. In
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this instance, rejection of the implant by the immune system or remote effects may occur
[125]. With these difficulties, it is apparent that conventional implant technology leaves
much to be desired.
Recent advances in biomedical research have focused on controlling the body’s
response to implant materials by careful selection and engineering. If the effect of these
biomaterials on the body can be controlled, implants with much better function and
applicability can be imagined. Numerous attempts to modulate the body’s response have
been investigated. For example, the use of materials such as Dacron® and Gore® for use
in vascular grafts and the use of modern alloys in articular replacements have greatly
improved the function of these implants and reduced the incidence and severity of
adverse reactions in the body. The poor biointegration often seen with these materials
and their inherent inability to repair damage still represent significant deficits in their
long-term function [132]. The development of more complex biomaterials remains a
major area of research and shows great promise to address a number of critical needs in
the medical field.
The body’s response to biomaterials is very similar to the previously described
post surgical adhesion formation process (see Section 2.2). These parallels provide
insight into the desired properties of materials employed for the prevention of PSA.
Strategies that have previously been shown to attenuate the foreign body response
observed with implanted biomaterials are expected to provide excellent opportunities for
reducing the incidence of PSA. It is thought that, by minimizing the body’s response,
development of an extended FGM matrix can be controlled in much the same way that
many successful biomaterials avoid a strong foreign body response.
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2.5.3. Polyethylene Glycol
One particular material that is the subject of much current research is
polyethylene glycol (PEG). This material, often referred to as polyethylene oxide (PEO)
in higher molecular weight forms, has been shown to be biocompatible in a number of
applications and is under investigation for a variety of additional uses. PEG consists of a
series of repeating –(CH2CH2O)– units with hydroxyl terminations at both ends. This
structure results in PEG’s having an amphiphilic nature that renders it resistant to protein
adsorption.
While soluble in many organic solvents, PEG is highly hydrophilic and has been
shown to form PEGylated surfaces with a hydrated layer with a large excluded volume
and high steric stabilization [90-91]. Such a surface presents few binding sites for protein
interactions, and the adsorption of protein and subsequent adhesion of cells is strongly
inhibited. Recent studies incorporating low concentrations of PEG into polylactic acid
have been shown to reduce the level of cellular adhesion dramatically [133]. In addition
to its resistance to fouling, PEG can also form hydrogels.

In this form, PEG’s

consistency can be tailored to match the native or surrounding tissue for implant
applications.
This unique structure, coupled with its lack of toxicity, has led to PEG’s
investigation for use in numerous biomaterials applications.

Many controlled drug

delivery systems exploit PEG to create “stealth” technologies. Nanoscale materials can
be injected into the bloodstream; since they are unable to be seen by immune cells, they
can achieve very long circulation times and extend drug delivery therapy. Other drug
delivery systems employ PEG in stationary reservoir systems to avoid fibrous capsule
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formation [134]. More recently, PEG has been investigated for use in biosensor and
numerous other biomedical applications [135]. This wide-ranging applicability at
rendering surfaces resistant to cell and protein adhesion and well-characterized
biocompatibility suggest that PEG should be an ideal material for use in PSA adhesion
technologies.
2.6.

Targeting and Controlled Delivery
Successful medical treatment of many conditions is hampered by numerous

factors. In order to treat a disease in the body, it is often necessary to deliver a drug to a
specific area and to maintain therapeutic concentrations for an extended period of time
[134]. The desire to maintain these concentrations, frequent dosing at high levels can lead
to systematic complications. For example, many chemotherapies for the treatment of
cancers require daily dosing and can lead to side effects including nausea, loss of hair,
and anemia [136-140].
In order to maximize the efficacy of treatments and to reduce these side effects, it
would be advantageous to deliver the desired drugs to the affected areas of the body and
release them at a rate that would maintain the therapeutic concentration in the local area.
Vigorous research is underway to investigate technologies that will facilitate such
treatments. Many advanced drug delivery systems have been designed to extend the
therapeutic treatment window. These systems vary from relatively simple extended
release tablets to complicated pulsatile delivery systems with feedback loops that respond
to changes in the physiological environment [134, 141-145].
Another technique that can be used to minimize side effects while achieving the
maximum benefit from a treatment relies on delivering the therapy only to the affected
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area(s) of the body. Simple embodiments of this concept include external application of
ice to swollen joints, injection of anti-inflammatory drugs, or the application of topical
antibiotics. The treatment of many disease conditions, however, requires that potentially
toxic drugs be delivered to specific areas within the body. In order to address this goal,
drug delivery systems have been developed to deliver agents specifically to affected areas
of the body.
For therapeutic agents delivered via the vasculature, this targeted drug delivery
can occur through two unique mechanisms. Passive targeting often relies on the enhanced
permeability and retention (EPR) effect to facilitate delivery of drugs to tumor sites [146149]. Because of their rapid growth, tumor sites often develop vasculature with large
pores. This “leaky” vasculature allows nanosized drug carriers to reach these sites, where
they are able to release therapeutic agents at the pathological sites. Alternatively, active
targeting relies on specific ligand-target interactions to direct drugs to the desired site in
the body. Recent developments in chemical and biochemical techniques have led to
advances in the area of active targeting. By designing drugs or drug carriers to seek out
these specific sites in the body, the efficacy of therapeutic treatments can be enhanced
while the potential for adverse side effects can be greatly reduced [146, 150-152]. Major
advances in this field have demonstrated excellent results in the treatment of numerous
cancers, diabetes, and vascular disease [153-160].
This active targeting can be carried out using a variety of targeting units.
Antibodies for specific molecules, including fibrin, can be conjugated to nanoparticles or
liposomes in order to direct targeting [161]. These antibodies, however, are not ideal for
targeting of small molecules. Because of their very large size (~ 150 kDa), the antibody
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could mask the effect of polymers delivered to surfaces. In addition, since they are
biologically derived, they are likely to elicit an undesired response in the body. Aptamers,
small strands of nucleic acid, can also be employed to provide specific binding to
molecules [162-163]. These targeting units can be isolated by iterative selection and
amplification in vitro from a random pool of nucleic acid strands. A similar approach
using bacteriophages for amplification can be employed to select peptide units for
targeting [164]. These targeting approaches result in the identification of small, easily
synthesized molecules that can then be incorporated onto the therapeutic molecule or
carrier [163, 165-167].
These small targeting units provide advantages over antibody targeting. First,
since the targeting unit is relatively small, multiple groups can be incorporated into the
structure to amplify the effect of targeting without the likelihood of masking the
protective properties of the polymers. In addition, since they are not biologically derived,
they have a low probability of eliciting an immunological response from the body.
2.6.1. CREKA Targeting Peptide
A particular targeting technology has recently been developed as a means to target
drug carriers to tumor cells based on the presence of clotted plasma proteins that
accumulate due to the leaky vascular associated with rapidly growing tumors [168-170].
This new targeting agent, based on the pentapeptide unit Cysteine-Arginine-Glutamic
Acid-Lysine-Alanine (CREKA), has been shown to enhance delivery of nanoparticles
and nanoworms to tumor sites. In initial investigations, superparamagnetic iron oxide
(SPIO) nanoparticles were conjugated with CREKA and successfully targeted to growing
tumors in mice [171]. If the fibrinogen knockout mice were used in the experiment, no
26

targeting was observed, confirming that the targeting mechanism relies on specific
interaction of the peptide unit with clotting proteins. Subsequent studies verified the
ability to target clinically approved chemotherapeutic nanoparticles in mice [172]. The
effect of changes in the shape of the targeted nanoparticle and the density of targeting
peptides has also been carried out [173]. This peptide has also been shown to be effective
at targeting nanoparticles to atherosclerosis plaques for diagnosis and therapy [174].
In order to improve the understanding of CREKA and to develop functional
analogs, several modeling studies using molecular dynamics have been conducted. Initial
modeling of the three-dimensional structure of the peptide in aqueous solutions and on
the surface of nanoparticles indicated that the conformation is unchanged by surface
attachment via the cysteine residue [175]. Subsequent models indicated the relative
stability of the three-dimensional structure of the CREKA unit with the addition of dye
molecules or with substitution of protease-resistant arginine analogs [176-177]. While the
nature of the interactions of this peptide with fibrin is not well understood, the
effectiveness of its targeting ability and its robust three-dimensional structure make it an
attractive ligand for the targeting of materials to fibrin.
2.7.

Conclusion
Post-surgical adhesions represent a significant clinical complication that affects a

large patient population. To address this multifaceted problem, a range of methods were
developed. Although use of physical material barriers provides the best results, no single
method has proven to be effective in all instances, to date. This failure is most likely due
to the complexity of PSA formation, the uniqueness of each surgical procedure and
patient, and lack of understanding of the underlying mechanism of PSA etiology and
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successful prevention. PSA remains a serious clinical problem. New methodologies to
improve material/device performance at a mechanistic level are a necessity for the
success of PSA barriers in the future. In addition, novel materials must be designed and
formulated to address all pertinent aspects of the PSA formation (e.g., physical, chemical,
inflammatory, oxidative, and wound healing) in order to maximize the potential for
clinical success. In this regard, biomaterial engineers could make crucial contributions
toward eventual elimination of PSA formation.
This dissertation describes the design, synthesis, and evaluation of a series of
polymeric biomaterials for use as prophylactic adhesion barriers. Based on a thorough
understanding of the underlying biochemistry and pathology of PSA formation, the
materials were specifically designed to interrupt the cascade of events that leads to
adhesion formation. Applying tools from polymer chemistry, organic chemistry, and
analytical chemistry, these materials were synthesized and fully characterized. The
function of these materials was evaluated in model systems, and the relationship between
their structure and function was assessed using statistical techniques. Finally, the ability
of these materials to inhibit PSA formation in vivo was evaluated.

Copyright © John M. Medley 2010
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Figure 2-1

An example of intestinal post-surgical adhesion (PSA) formation.
In a rat model, sections of mecum and ileum were abraded using dry gauze
until hemorrhage formed. Fourteen days post surgery, adhesion formation
was visualized. Figure reproduced with permission from Kutlay, et al.
[178].
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Figure 2-2

Stages and time course of the wound healing process.
Initially, a high concentration of fibrin is observed in the peritoneal fluid.
Polymorphoneutrophils PMNs are observed within approximately two
days post tissue-trauma, followed by macrophages. Reperitonealization
occurs with the appearance of mesothelial cells within the first five days,
and vascularization begins within 1 week following tissue damage.
Adapted from [126].
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Table 2-1

Timeline of events occurring during post-surgical adhesion formation.

1.

Damage to the peritoneal mesothelium exposes an acellular, denuded
surface, known as the “basement membrane”, which consists primarily of
type I collagen, type II collagen, fibronectin, and laminin [6, 8].

2.

As the vasculature constricts, homeostasis is obtained and the coagulation
cascade begins with the deposition of fibrin [8].

3.

The quantities of fluid and plasma proteins increase near the site of injury
and an inflammatory exudate develops within the peritoneal fluid [7].

4.

The composition of this exudate, initially consisting primarily of
neutrophils, changes. If there is no infection, it becomes rich in
macrophages over the course of 24 hours [7-8].

5.

Epithelial cells are deposited on the surface of the injury by a process
called “island implantation” and re-epithelialization of the peritoneal
surface proceeds [7].

6.

The fibrin gel matrix (FGM), considered the “principal player in adhesion
formation,” consists of fibrin, fibronectin, hyaluronic acid,
glucosaminoglycans and proteoglycans, and forms 72-108 hours after
surgery [7-8].

7.

The FGM is remodeled and strengthened, for approximately 1 month [89].

8. The FGM is slowly replaced by fibrous collagen molecules and
vascularized in a process controlled, at least partially, by macrophages [8].
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Table 2-2

Structure of Materials Used for Adhesion Prevention

Hyaluronic Acid (HA)

Carboxymethylcellulose
(CMC)

Phospholipid

“Adept” Icodextrin

Polyethylene Glycol
(PEG)
Poly (L-Lysine)

Poly (L-Glutamate)

Polyethylene (PE)

Poly
(Tetrafluoroethylene)
(PTFE)
Cellulose

“SprayGel” System
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Table 2-3

Summary of Techniques used to Prevent Post Surgical Adhesions
Application
Method

Biodegradability

Level of Tunable Properties

Non- Suturing of Damaged
Peritoneum

N/A

N/A

N/A

Use of Laparoscopic
Procedures

N/A

N/A

N/A

Other Technique Changes
(Non-powdered gloves, nonuse of drainage tubes, increased
tissue oxygenation)

N/A

N/A

N/A

IP injection

Yes

Dose, timing, and selection of
the therapeutic agent

Modification of
Surgical Technique

Technology

Adhesion Barriers
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Peritoneal Instillates

Pharmaceutical
Interventions

Anti-Inflammatories

Antioxidants

IP injection

Yes

Dose can be altered

Fibrinolytic Agents

IP Injection

Yes

Dose can be altered
Dose and timing of the
therapeutic agent can be
altered
MW and dose of HA can be
optimized

Level of Success
Significant decrease in PSA formation, but adoption of this practice by
surgeons problematic
Significant decrease in PSA formation, but:
•
Application of technique is limited to certain surgeries
•
Precludes use of many other adhesion-reduction techniques
Significant decrease in PSA formation, but adoption of this practice by
surgeons is problematic
Moderate success because of the associated risk of side effects
Very successful.
•
Vitamin E interrupts several parts of the adhesion formation
mechanism.
Moderately successful but has potential for immunogenic response and
reduced hemostasis

References
[1-2, 13, 24-26]
[34-36]

[1-2, 31, 33]

[37-38]

[45-46]
[9, 49-50, 52-54]

Chymase Inhibitors

Oral Delivery

Yes

Moderately successful

[59]

Hyaluronic Acid and its
Derivatives

IP injection

Yes

Moderately successful

[64-71, 76-77]

Phospholipids

IP injection

Yes

Dose can be optimized

Very effective.
•
The zwitterionic nature of the phospholipids allows them to bind onto
the epithelial cell membranes and provide lubrication

[79-82]

Hydroflotation Initiators
(“Adept”)

IP Injection

Yes

MW and dose of the starch
molecules can be optimized

Moderately successful

[83-89]

Poly(ethylene glycol)

IP injection

Yes

MW and concentration of
PEG solution can be
optimized

Moderately successful:
•
Significant decrease in number and collagen content of PSAs

Polytetrafluoroethylene
(“Gortex Surgical
Membrane”, “Preclude”)

Film placed
directly on the
damaged tissue

No

Physical properties of the
mesh can be controlled

Oxidized Regenerated
Cellulose (“Interceed”)

Film placed
directly on the
damaged tissue

Yes

MW, degree of oxidation, and
the physical properties of the
film can be controlled

Cross-Linked Hyaluronic
Acid Gel (“Seprafilm”)

Film placed
directly on the
damaged tissue

Yes

MW and degree of the crosslinking can be optimized

in vivo Polymerization of
Poly(ethylene glycol) (“Spray
Gel”)

In vivo spray
polymerization

Yes

MW and degree of
polymerization can be
optimized

Moderately successful:
•
Non-degradable; it remains in site and must be removed with another
surgical procedure
•
Requires suture fixation
•
Incompatible with laparoscopy
Moderately successful:
•
Thrombogenic
•
Difficult to handle
•
Incompatible with laparoscopy
Very successful:
•
Adheres to the peritoneum
•
Degrades
•
Is not procoagulant
But causes:
•
Severe inflammation
•
Abscess formation
•
Must be placed directly on the damaged tissue
Very effective; can be employed with laparoscopic procedures

[4, 90-91]

[95, 99-102]

[48, 102, 107]

[102-104]

[105-106, 110]

Table 2-4
Tissue(s)
Involved

Abdominal
Wall

Animal Models used to Evaluate Post Surgical Adhesion Prevention
Strategies
Animal
Model

Pros

Cons

References

Mouse

Measure both extent and
type of adhesion

Semiquantitative scoring

[33]

Rat

Quantitative analysis of
adhesion area

Rabbit

Surgical damage
carefully controlled

Intestinal wall

Rat

Intestine /
Abdominal
Wall

Rabbit

Semiquantitative scoring

[80-81]

Semiquantitative scoring

[111-112]

Surgical damage
carefully controlled

[82]

Rabbit

Semiquantitative scoring

[38, 69,
113, 179]

Hamster

Semiquantitative scoring

[59]

Semiquantitative scoring

[105]

Semiquantitative scoring

[31, 97]

Pig
Uterus

Uterus
Reformation

[93-94]

Internal control possible
by treating two uterine
horns separately

Rabbit

Internal control possible

Rat

Internal control possible
Quantitative area result

Mouse

Multiple Adhesion

[46, 89,
100]
Semiquantitative scoring
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[64]

Table 2-5
Score

Scoring Methodology Employed to Evaluate Post Surgical Adhesion
Prevention Strategies

Extent of Adhesion

Severity

Degree

0

None

No adhesions

No adhesions

1

1-25%

Filmy, avascular

Adherent tissue separate
with gentle traction

2

26-50%

Vascular and/or opaque

Tissue layer separation
requires moderate traction

3

51-75%

Cohesive attachment

Tissue layer separation
requires sharp dissection

4

76-100%
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CHAPTER 3. RESEARCH GOALS

3.1.

Introduction
In this project, we have developed a series of targeted polymeric biomaterials and

investigated their utility as a prophylactic treatment for the prevention of post surgical
adhesions. In order to address this real-world problem, the integration of knowledge from
numerous fields is required. The molecular design of the final polymer is based on the
biological and biochemical environments of interest and the desired mechanical and
biomaterial properties. Knowledge of organic chemistry and analytical chemistry
facilitates the synthesis and characterization of these materials, and the framework of
chemical engineering integrates these varied fields and provides the basis for functional
evaluation and enhanced understanding.
By applying a fundamental understanding of the biochemistry, physiology, and
pathology of adhesion formation, the materials were specifically designed to meet this
clinical need. Using well controlled polymerization chemistry and subsequent
functionalization, several structural properties were varied and the affect of this structure
was evaluated in numerous in vitro models. Finally, the results of these investigations
were employed to select a combination of materials to be evaluated in vivo in a rabbit
model. This methodical, ground up approach, provides unique insight into the
relationship between the molecular structure of these materials and their performance as
adhesion barriers and increases the likelihood for the development of a viable method to
address this clinical need. This approach to biomaterial development and its initial success
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should lead to significant additional research into the use of self-assembled systems for PSA
prevention and in other applications, including tissue adhesives and oral barriers.

3.2.

Objectives and Significance
The following general hypothesis was proposed to direct this research:

Polymeric materials can be designed to assemble in situ by targeting biomarkers
of tissue damage and provide protection from the formation of post surgical
adhesions.

In order to investigate this hypothesis, the project was conducted in three distinct
stages, described below as specific aims, each of which was carried out to test a specific
hypothesis.
3.2.1.

Specific Aim 1: Design, synthesis, and characterization of polymers to be
used for the in situ formation of adhesion barrier.
In order to develop a new material for use as a prophylactic treatment to prevent

PSA formation, three stages of synthesis and characterization were addressed:

1.

Synthesis of block copolymers incorporating poly(methacrylic acid),
reactive methacrylate monomers, and poly(ethylene glycol) functionality
with highly-controlled molecular weight and polydispersity.

2.

Functionalization of polymers for the addition of cross-linkers and fibrinspecific peptides.
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3.

Implementation of polymer characterization methods using available tools,
including proton nuclear magnetic resonance spectroscopy (1H-NMR), gel
permeation chromatography (GPC), and high performance liquid
chromatography (HPLC).

3.2.1.1. Hypothesis #1
Group transfer polymerization can synthesize a variety of methacrylic acid
based polymers with multiple functionalities and precisely controlled
molecular architecture for in vitro evaluation.
3.2.1.2. Significance and Outcomes
Efforts to test this hypothesis are described in Chapter 4. As described in this
section, we have fully implemented the methodology to perform group transfer
polymerization (GTP) in our laboratory. The ability to polymerize various monomers has
been established, as has a selective deprotection strategy, allowing multiple
functionalities to be added sequentially. Methods to characterize these materials using
1

H-NMR, GPC, and HPLC have been realized. We have synthesized diblock copolymers

containing functionalized methacrylic acid units with targeting moieties and pendant
polyethylene glycol chains. These polymers exhibit precise control of both the molecular
weight and polydispersity of individual polymer blocks.
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3.2.2. Specific Aim 2: Investigation of non-targeted statistical and block
copolymers interactions with model surfaces.
The second phase of this research focused on the evaluation of non-targeted
polymeric biomaterials using a variety of in vitro test methods. This stage can be divided
into three sub-stages:

1.

Investigation of the kinetics, thermodynamics, and conformation of nontargeted polymer adsorption to model surfaces.

2.

Evaluation of polymeric biomaterials to block non-specific protein
adsorption.

3.

Reduction of cellular attachment by non-targeted block and statistical
copolymers on positively charged self-assembled monolayer surfaces.

3.2.2.1. Hypothesis #2
Non-targeted block copolymers with high charge density will interact more
readily with charged model substrates as compared to statistical copolymers. The
kinetics and thermodynamics of these interactions and the structure of the
resulting surface layer can be characterized by quartz crystal microgravimetry
and cellular attachment assays.
3.2.2.2. Significance and Outcomes
The quartz crystal microbalance was proven to be an effective, efficient method to
probe the interaction of the polymers of interest with positively charged model surfaces.
By fitting a simple adsorption model to the observed adsorption phenomena, it was
39

possible to quantify the kinetics and equilibrium surface coverage of these materials. This
work, described in Chapter 5, supported the hypothesis that non-specific protein
adsorption can be modulated by varying the structure of the polymer. Finally, depending
on the particular molecular architecture employed, these materials also proved effective
at reducing the level of cellular attachment to surfaces.
3.2.3.

Specific Aim #3: In vitro evaluation of targeted copolymers to reduce events
leading to fibrin gel propagation and assessment of targeting specificity.
The final aspect of this research project focused on the investigation of targeting

in order to enhance the ability of block copolymers to function as desired. This work was
carried out in two phases:

1.

Investigation of targeted block copolymers to modulate aspects of fibrin
gel matrix propagation, including fibrinogen adsorption, fibrin gel
propagation, and cellular attachment.

2.

Evaluation of interactions of targeting peptides and targeted polymers with
fibrin and fibrinogen.

3.2.3.1. Hypothesis #3
Using targeting peptides, block copolymers can be tailored to bind effectively to
markers of damaged tissue. Binding to fibrin, these PEG containing polymers
will render the growing fibrin gel matrix less susceptible to subsequent
fibrinogen deposition and cellular attachment, thereby attenuating propagation
of the FGM.
40

3.2.3.2. Significance and Outcomes
The investigation of hypothesis #3 represents the culmination of the work carried
out in the previous investigations. As described in Chapter 6, the incorporation of
targeting peptides and the careful control of molecular architecture can be used to
moderate the propagation of the fibrin gel matrix. The polymers interact strongly with
fibrin surfaces and reduce the rate and degree of subsequent fibrinogen deposition. In
addition, they provide protection against cellular attachment on model fibrin surfaces.
The investigations described in Chapter 7 confirm the ability of these targeted
materials to interact with fibrin(ogen). Although the effect was less pronounced than
anticipated, the molecular architecture of the polymer affects the structure of the fibrin
fibrils in the growing fibrin gel matrix. Finally, the targeting peptides, as well as the
scramble peptide used as a control, both interact strongly with solution phase fibrinogen
and result in a large conformational change in the protein.

Copyright © John M. Medley 2010
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CHAPTER 4. POLYMER SYNTHESIS AND CHARACTERIZATION

4.1.

Introduction
In order to test the hypothesis that polymeric materials can be employed to

assemble in situ and provide protection from the formation of post surgical adhesions, we
first set out to design the appropriate materials to test. By designing this material from the
ground up, we were able to select and tune the biocompatibility of the materials, include
desired functionality, and tailor the architecture of the molecules. Employing group
transfer polymerization allowed the synthesis of block copolymers containing various
functionalities and provided precise control over the molecular weight of the various
blocks. To minimize the potential for adverse biological interactions, the selection of
materials was limited to those that have previously been shown to exhibit
biocompatibility. Specifically, non-toxic and non-immunogenic materials were required.
In addition, the potential to incorporate multiple functional groups and to control the
molecular weight of the polymerization were desired. Finally, materials were selected
that were expected to provide excellent barrier properties and prevent the adsorption of
proteins.
Methacrylic acid was selected as the monomer for the polymer backbone for
several reasons. First, methacrylate polymers have been employed and have shown
excellent biocompatibility in many applications [180-183]. While some studies have
employed polyacrylic acid as an adjuvant to heighten the body’s immune response to
vaccination formulations, the nature of this reaction is believed to stem from the high
molecular weight and the large concentration of acidic units employed [184-185]. While
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we anticipate that these effects can be modulated by controlling the polymer architecture,
they will be investigated in future studies. Finally, methacrylic acid can be readily
functionalized with a variety of functional groups, many of which are commercially
available or can easily be prepared in the laboratory.
In order to provide resistance to the adsorption of proteins and interrupt
subsequent adhesion formation, polyethylene glycol (PEG) was chosen. This polymer has
been used in a variety of biomaterials applications in order to provide protection from
protein adsorption and from immunological response in vivo [118, 134]. Because of its
highly hydrophilic nature, water associates strongly with PEG in aqueous environments
and the polymer typically exists in a gel state. This structure resembles the extracellular
matrix and provides high steric protection in the body [90-91]. Numerous examples can
be found employing PEG to create “stealth” drug delivery systems with long circulation
times [134, 186-188]. To incorporate PEG into our polymer system, commercially
available methoxy polyethylene glycol methacrylate with a PEG chain length of
approximately 25 PEG repeat units (MPEGMA1100, Aldrich) was selected for use.
The target molecular weight for polymer synthesis was chosen to meet a variety
of requirements. First, it has previously been demonstrated that the maximum reduction
in protein adsorption is observed with PEG chains with a molecular weight of 5,000
g/mol [189]. The maximum molecular weight of the polymer was set at 50,000 g/mol to
ensure rapid renal clearance of any material entering the bloodstream [134]. The initial
polymer synthesized for use in this investigation incorporated a block of t-butyl
methacrylate (TBMA) and a block of MPEGMA1100; the target molecular weights of
these units were each set at 5,000 g/mol.
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In order to assess the relationship between polymer structure and function, and to
ensure repeatability between synthetic batches, it was necessary to employ a highly
controlled

polymer

synthesis.

Group

Transfer

Polymerization

(GTP),

shown

schematically in Figure 4-1, was utilized to synthesize the backbone polymers used in
these studies. This technique allows the synthesis of polymers with controlled molecular
weight and polydispersity. In addition, statistical and block copolymers can readily be
created by reacting multiple monomer units with either simultaneous or sequential
monomer addition.
4.2. Materials and Methods
4.2.1. Synthesis and Characterization of Protected Backbone Polymers
Using modifications of previously published reaction schemes, the synthesis was
carried out as shown in Figure 4-2 [190-194]. Solvent was prepared by drying 450 ml
THF (Mallinckrodt) over a mixture of sodium (4 g, Aldrich) and benzophenone (8 g,
Aldrich) until the purple color characteristic of the dianion was observed. The proton
scavenger bis(dimethylamino) methylsilane (ABCR, Gelest) was distilled under vacuum
and stored in a freezer under argon prior to use. TBMA (Aldrich) and (MN = 300,
MPEGMA300, Aldrich), was passed through an inhibitor removal column, distilled, mixed
with ABCR (2 wt%), and stored in a freezer under argon prior to use. MPEGMA1100 was
dissolved in inhibitor free THF (Aldrich), passed through an inhibitor removal column,
and dried under vacuum overnight. This macromer was dissolved in dry, air-free THF to
a concentration of 0.4 g/mL, mixed with 2% ABCR, and stored under argon in freezer
prior to use. 1-methoxy-1-(trimethylsiloxy)-2-methyl-1-propene (MTS, Gelest), was
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vacuum distilled and stored under argon in freezer prior to use. The catalyst,
tetrabutyyammonium bibenzoate (TBABB) was prepared as has previously been
described and stored under nitrogen prior to use [195]. Prior to polymerization, all
glassware was dried overnight at 180 oC, assembled hot, and flamed under vacuum to
remove residual water.
Approximately 10 mg TBABB was added to the reaction flask under inert
atmosphere. Approximately 15 mL of dry, air free THF was added to the flask by solvent
transfer. The initiator, (MTS, 93.3 mg, 0.53 mmol) was added via syringe under argon
and allowed to stir for 15 minutes at room temperature. To form a block copolymer, 1.97
g TBMA (13.9 mmol) was added to the reaction vessel via syringe under argon. No
apparent exotherm was observed. The reaction was allowed to proceed under argon for
30 minutes, at which time approximately 5 mL was removed for analysis and quenched
with methanol. A solution of the second monomer, MPEGMA1100, (5 mL, 1.8 mmol) was
then added to the reaction vessel and allowed to react for 90 minutes. The reaction was
quenched with methanol, the solvent was removed with vacuum, and the product was
dried for 48 hours under vacuum. Based on the stoichiometry, the molecular weights for
the TBMA block and the MPEGMA1100 block were predicted as 3,700 and 5,900 g/mol,
respectively, and the ratio of TBMA blocks to MPEGMA1100 was predicted to be 5.1:1.
Block copolymers of MPEGMA300 and TMBA were prepared similarly.
Additionally, statistical copolymers were synthesized using the same technique, with
simultaneous addition of the two monomers. Finally, a homopolymer of TBMA was
prepared using the same technique. The resulting polymers were dissolved in deionized
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water and purified by triplicate ultrafiltrations with Ultracel Amicon YM membranes
with appropriate molecular weight cutoffs and isolated by lypholization.
4.2.2. Deprotection of tert-Butylmethacrylic Acid Group
A modification of a previously described procedure was used to convert the
TBMA groups to methacrylic acid groups [194]. As shown in Figure 4-2, hydrolysis was
carried out by refluxing in 1,4-dioxane (Aldrich) with p-toluenesulfonic acid (PTSA,
Aldrich) for 20 – 96 hours. The resulting polymers were purified by triplicate
ultrafiltration and isolated by lypholization.
The polymers were characterized by gel permeation chromatography (GPC) and
by proton nuclear magnetic resonance spectroscopy (1H-NMR). GPC was carried out
using a Shimadzu Prominence High Performance Liquid Chromatography system
equipped with a Waters Refractive Index Detector (RID). All analyses were conducted in
THF using Waters HR1 and HR2 columns in series with an Agilent PLGel Mixed B
column, a flow rate of 1.0 mL/min, and referenced to narrow molecular weight
polystyrene standards (Polymer Laboratories). The molecular weight distribution of the
polymers was determined using the Shimadzu LabSolutions software.
Proton NMR analysis was conducted by dissolving the polymer in deuterated
chloroform (Cambridge Isotopes) and measuring the resonance with a Varian Gemini 200
MHz NMR spectrometer. Mestralab Research’s MNova software was employed to
analyze the NMR spectra.
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4.2.3. Polymer Conjugation with N-Aminoethylmaleimide Crosslinker
Peptide functionalization of polymers was achieved through sulfhydryl directed
maleimide chemistry. Maleimide was introduced into the structure of the fully
deprotected polymers by the coupling of N-aminoethylmaleimide trifluoroacetic acid
(NAEM, Aldrich) [196-197]. This moiety was covalently attached to the polymer via a
stable amide linkage, leaving the maleimide group available for subsequent peptide
conjugation.
As shown in Figure 4-3, the primary amine group of the crosslinker was
conjugated to the free acid groups in the polymer chain to form amide bonds using well
known diimide chemistry [198-199]. Two equivalents of NAEM, based on the number of
free acid groups present, were combined with the polymer (1 equivalent of acid groups)
and 1.1 equivalent of N,N’-dicyclohexylcarbodiimide (DCC, Aldrich) and dissolved in
acetonitrile (ACN, Fisher). This reaction mixture was stirred at room temperature in the
dark for 2 hours. Successful conjugation was indicated by the precipitation of insoluble
N,N’-dicyclohexylurea (DCU) precipitate that began to form after approximately 5
minutes of reaction. After reacting for 2 hours, the excess DCC was quenched by adding
excess acetic acid (HAc, Fisher) and stirring for 10 minutes. The DCU was then removed
by centrifugation, leaving a clear yellow solution.
Excess NAEM was removed from the reaction mixture by repeated aqueous
extraction from diethyl ether. Upon dissolution in ether, the reaction mixture formed a
cloudy liquid, indicating the insolubility of NAEM in the solvent. The clear ether layer
that remained after extraction was evaporated. The white solid product was dissolved in
acetone, and the solvent was removed by evaporation. HPLC analysis was conducted on
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the Shimadzu Prominence HPLC system to confirm the purity of this product. This
analysis was carried out with a Restek Viva C18 5 µm 4.6 x 150 mm HPLC column at a
controlled temperature of 40 oC with an isocratic mobile phase consisting of 90% DI
water with 0.1% trifluoroacetic acid (TFA, Aldrich) and 10% methanol (Fisher). This
material was stored at -20 oC for subsequent peptide conjugation.
4.2.4. Conjugation of Peptides to Polymer
Two five unit oligopeptides were incorporated in the crosslinker-conjugated
polymers via the specific reaction between the sulfhydryl group on cysteine and the
maleimide group on the crosslinker. Both peptide chains included the amino acids alanine
(A), arginine (R), cysteine (C), glutamic acid (E), and lysine (K). The first peptide
employed, CREKA, was employed to target the polymers to fibrin, while the second
peptide, CAERK, was used as a control. Both of these materials were produced
specifically for this study by Celtek Biosciences.
The peptide conjugation reaction was carried out at room temperature in a
solution containing 50% ACN and 50% PBS as shown in Figure 4-4. The NAEMconjugated polymer was dissolved in this solution, and the desired amount of peptide (3-9
peptides per polymer chain) was added to the solution. This reaction mixture was stirred
at room temperature in the dark for five hours. Excess cysteine was added to consume
unreacted maleimide groups, and the reaction was allowed to proceed for one hour. After
removing the solvent in vacuo, approximately 3 mL of acetone was added. Insoluble salts
were removed by centrifugation, and the product was isolated by evaporating the solvent
with a stream of dry nitrogen.
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4.2.5. Purification of Polymer-Peptide Conjugates
HPLC analysis was conducted to assess the purity of the reaction mixtures. As
shown in Figure 4-5, the reaction mixture contained several products. In order to achieve
a pure product for analysis, preparative HPLC was employed to isolate the desired
peptide conjugate from the reaction mixture. The Shimadzu Prominence HPLC system
was used, with a Shimadzu Viva C18 21.2 x 150 mm column. The isocratic mobile phase
consisted of 90% DI water with 0.1% trifluoroacetic acid (TFA, Aldrich) and 10%
methanol (Fisher). The polymer conjugate, which eluted around 7 – 10 minutes, was
isolated by collecting appropriate fractions, and the solvent was removed in vacuo. The
purity and identity of the products was confirmed by subsequent HPLC and 1H-NMR
analysis.
4.3.

Results and Discussion

4.3.1. Polymer Synthesis and Characterization
In order to synthesize the backbone polymers for this study with the desired level
of control over the molecular architecture, it was necessary to employ group transfer
polymerization. Attempts to use anionic polymerization proved to be ineffective due to
the low temperature required. Although the TBMA monomer is readily soluble in THF at
-78 oC, the MPEGMA monomer was insoluble at this temperature. Group transfer
polymerization (GTP) overcomes this limitation, as it can be conducted at ambient
temperature. While it allows the desired control over the molecular architecture, the use
of GTP introduces additional complications into the synthetic scheme. Because GTP is
highly susceptible to proton quenching, it is necessary to employ aprotic monomers and
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anhydrous reaction conditions. Since it was desired to synthesize polymers with acidic
functional groups, synthesis of the polymer backbone was carried out with protected
monomers using standard Schlenk techniques to maintain inert reaction conditions. The
desired functionality was then introduced into the polymer by deprotection and
subsequent conjugation reactions.
A representative the gel permeation chromatogram of the protected polymer is
shown in Figure 4-6. As shown in Table 4-1 and Table 4-2, the polymers were
synthesized with low polydispersity and had molecular weights that were in close
agreement with the molecular weights predicted from stoichiometry. Each polymer was
analyzed by 1H-NMR in deuterated chloroform to confirm the structure and determine the
relative number of PEGMA units to TBMA units. The resulting NMR, shown in Figure
4-7, confirms the successful synthesis and purification of the desired polymer. The large
peak at • = 3.61 ppm corresponds to the ethyl ether peaks of the PEG chain, while the
peak at • = 3.36 ppm represents the three protons on the methyl ether terminus of the
PEG chain. The peak at • = 1.40 ppm arises from the t-butyl ether group on the TMBA
unit, while the broad peaks at • ≈ 1.1 ppm and • ≈ 1.8 ppm result from the methyl and
methylene groups in the polymer backbone. The absence of peaks in the range from 5.5 –
6.5 ppm indicates that no unreacted monomer remains after purification. By comparing
the areas of t-butyl ether peak to the area of the methoxy peak, it is possible to determine
the ratio of TBMA groups to PEGMA groups in the polymer. Combining this result with
the molecular weight data obtained from the GPC, the number of TBMA and PEGMA
monomers in each polymer was determined. These results, also summarized in Table 4-1
and Table 4-2, agree well with the predictions based on stoichiometry.
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Since the deprotection of the TBMA group results in the formation of methacrylic
acid groups along the polymer chain, GPC of this product using the previously described
method was not practical. Instead, the degree of TBMA deprotection in the polymer was
determined by monitoring the ratio of TBMA to PEGMA using 1H-NMR analysis.
Figure 4-7 shows the resulting spectrum for this deprotection. The decrease in this ratio
indicates 80% deprotection of the polymer in this instance. The increase in hydrophilicity
of the polymer is also indicated by the presence of residual water at • = 1.5 ppm. As the
hydrolysis reaction proceeded from 20 to 96 hours, the extent of hydrolysis increased
from 20% to 100%. Analysis of the reaction mixture confirmed that no cleavage of the
PEG ester bond occurred during deprotection. Using these results, along with the
previously determined molecular weight of the protected polymer, the molecular weight
of the deprotected polymer was calculated.
4.3.2. Polymer Conjugation with N-Aminoethylmaleimide Crosslinker
The success of the NAEM conjugation and purification procedure was confirmed
by 1H-NMR and by HPLC. As shown in Figure 4-8, HPLC analysis confirmed that this
purification procedure results in a pure polymer conjugate. The combination of the
unconjugated polymer (r.t. = 5.0 min) and the NAEM (r.t. = 2.4 min) resulted in the
formation of a new peak (r.t. = 7.7 min). Aqueous extraction from ether resulted in
quantitative separation of the excess NAEM (water layer) from the product (ether layer).
NMR analysis confirmed the incorporation of the crosslinker into the polymer structure.
As shown in Figure 4-9, the PEG peak (• = 3.57 ppm) and the polymer backbone peaks
(• ≈ 1.2) remain intact. In addition, the α -amide is indicated by the peaks at • = 1.71 and
• = 3.75, and the integrity of the reactive maleimide bond (• = 6.75 ppm) is confirmed.
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4.3.3. Conjugation of Peptides to Polymer
The peptide-polymer conjugates were successfully purified using preparatory
HPLC, as confirmed by analytical HPLC and 1H-NMR analysis. HPLC analysis of the
reaction mixture, shown in , the reaction mixture contained numerous products. By
collecting the fraction of the preparative HPLC eluent from 7 – 10 min, the purified
product was isolated and showed a single analytical HPLC peak (r.t. = 3.9 min). Proton
NMR analysis of this product confirmed the successful incorporation of the peptide into
the structure. As shown in Figure 4-9, the disappearance of the maleimide peak (• = 6.75
ppm) confirms the complete reaction of the crosslinker. Multiple NMR peaks (• = 1.20 –
1.5 ppm and 2.9 ppm) indicates the presence of the peptide in the polymer structure.
Quantitative analysis of the peptide incorporation into the structure was frustrated
by the complex NMR spectrum and by the difficulty in making unambiguous peak
assignment. Fortunately, by monitoring the progress of the peptide conjugation with
HPLC, it is possible to confirm that the peptide is quantitatively incorporated into the
polymer structure. Figure 4-10 shows HPLC chromatograms for the starting materials
(CREKA and P1-N) employed for this reaction. As seen in the two chromatograms
collected from the reaction at later time points, it is evident that the starting materials are
both consumed, and that there is only one product peak. As a result of this rapid,
quantitative reaction between the sulfhydryl group on the peptide and the maleimide
group on the polymer, it is possible to determine the composition of the resulting polymer
based on the stoichiometry of the reactants. The materials employed in the untargeted
analysis and targeting studies are summarized in Table 4-1 and Table 4-2, respectively
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4.4.

Conclusion
The ability to synthesize and characterize functionalized diblock and statistical

copolymers for investigation as post-surgical prevention barriers has successfully been
demonstrated. The robust synthetic methodology that has been developed allows the
rapid synthesis of block and statistical copolymers of methacrylic acid and PEGMA.
These materials can be functionalized with targeting peptides. In order to ensure that
subsequent tests to ascertain the impact of changes in the molecular structure on material
performance, it is important to note that these materials can readily be isolated as pure
materials by preparatory HPLC. Using these techniques, we have prepared several
materials and initial analysis confirms the strong dependence of function on molecular
architecture. These techniques provide readily accessible methods that are capable of
avoiding many of the technical challenges that plague functional polymer synthesis.

Copyright © John M. Medley 2010
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Figure 4-1

Concerted mechanism for group transfer polymerization.
The initiator, 1-methoxy-1-(trimethylsiloxy)-2-methyl-1-propene (MTS)
reacts with the protected methacrylic acid group. The trimethylsilyl (TMS)
group is transferred from the initiator to the end of the polymer chain. This
“living” end propagates the polymerization until the reaction is terminated
[200].
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Figure 4-2

Reaction scheme for the synthesis of poly PEGMA1100-block-(TBMA-coMA) by group transfer polymerization.
In the presence of the initiator (MTS) and catalyst (tert-butylammonium
bibenzoate, TBABB), tert-butyl methacrylate (TBMA) monomer
polymerizes via group transfer polymerization. Subsequent addition of
poly(ethylene glycol) methacrylic acid (PEGMA) facilitates block
copolymer formation. The MA units are then deprotected by hydrolysis of
the t-butyl group in refluxing 1,4-dioxane with p-toluenesulfonic acid
(PTSA).
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Figure 4-3

Reaction scheme for the conjugation of N-aminoethylmaleimide (NAEM)
to deprotected polymer.
Functionalization of copolymer with the crosslinker (NAEM) is conducted
in the presence of dicyclohexylcarbodiimide (DCC) in acetonitrile (ACN).

56

Figure 4-4

Reaction scheme for the conjugation of peptide to NAEM functionalized
polymer.
When the crosslinker functionalized polymer is mixed with peptide, the
sulfhydryl group on the peptide unit reacts specifically with the maleimide
group on the crosslinker in a 50/50 mixture ANC and PBS at pH = 7.4.
Unreacted NAEM groups are then quenched by reaction with cysteine
groups to prevent subsequent reaction.
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Figure 4-5

HPLC analysis and purification of peptide conjugate.
The HPLC chromatogram for the unpurified reaction mixture (top)
indicates a mixture of products and unreacted starting materials.
Preparatory HPLC (bottom) was conducted to isolate the desired product
(r.t. = 7 – 10 min.). The purified material (middle) shown a single peak for
the desired product (r.t. = 3.9 min). The peak at 2.7 min. corresponds to
acetone, used as the injection solvent in this analysis.
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Figure 4-6

Sample GPC chromatogram for P2-Pro.
GPC was conducted and described and referenced to narrow molecular
weight distribution polystyrene standards. Triplicate analyses of this
material indicate that MN = 3,120 ± 150 g/mol (M ± SD), MW = 5,020 ±
280 g/mol, PD = 1.61 ± 0.04.
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Figure 4-7

1

H-NMR analysis of polymeric product.
Prior to hydrolysis (top), TBMA:PEGMA1100= 3.1 based on peaks at δ =
1.4 (t-butyl group) and δ = 3.35 (methyl ether), respectively. Hydrolysis
was determined by evaluating the change in peak ratio. The relative
change in TBMA intensity (bottom) indicates 80% hydrolysis was
achieved. The peak at δ = 1.55 indicates residual water bound to the
hydrophilic polymer.
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Normalized UV Absorbance
(220 nm)

Unconjugated Polymer
NAEM
Reaction Mixture
Water Layer
Ether Layer
2.0

4.0

6.0

8.0

Retention Time (min)
Figure 4-8

N-Aminoethyl Polymer Conjugate Purification.
Conjugation of polymer (r.t. = 5.0 min.) with an excess amount of NAEM
(r.t. = 2.4 min) yields a new peak in the chromatogram (r.t. = 7.7 min).
Multiple ether/water extractions of the excess NAEM from this reaction
mixture results in pure NAEM conjugate in the ether layer.
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Polymer in CDCl 3

NAEM-Polymer
Conjugate in CDCl 3

CREKA in D2O

CREKA-Polymer
Conjugate in Acetone-d6

Figure 4-9

1

H-NMR analysis of unconjugated polymer, NAEM conjugate, and
peptide product.
The unconjugated polymer (P1) indicates the presence of methyl and
methylene and groups from the methacrylic acid units (broad peak at • =
1.2 ppm). In addition, the ethylene glycol and terminal methoxy peaks are
clearly evident at • = 3.5 ppm and • = 3.4 ppm, respectively. Upon
conjugation with NAEM, the peaks from the aminoethyl group (• = 1.7
ppm) and the maleimide group (• = 6.75 ppm) appear. Upon addition of
the peptide (CREKA) and cysteine, several peaks corresponding to the
pentapeptide (• = 1.0 – 1.5 ppm, • = 2.9 ppm) are evident. In addition, the
disappearance of the maleimide confirms the reaction with sulfhydryl
groups.
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Normalized UV Absorbance
(220 nm)

t=7.5 hr.

t=50 min.

P1-N

CREKA
2.0

4.0

6.0

8.0

Retention Time (min)

Figure 4-10

HPLC chromatograms of quantitative conjugation reaction between
CREKA and NAEM conjugate.
When NAEM functionalized polymer is reacted with peptide (CREKA, r.t.
= 3.7 min), a new peak is formed (r.t. = 6.7 min). The peptide is
consumed, and only one product peak is observed. This product peak
forms within the first hour of reaction and remains unchanged thereafter.
These observations indicate the quantitative incorporation of the peptide
unit into the polymer.
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Table 4-1

Polymer
NP
EPC

Summary of Block and Statistical Copolymers used for Analysis of
Untargeted Polymers
Polymer Type

TBMA /
PEGMA

No Polymer

N/A

Degree of
Deprotection
(NMR)
-

N/A

Phospholipid
(Egg Phosphatidylcholine)

MN, CAL

MN, GPCa

PDGPCa

-

-

-

-

760*

-

-

PAA

Homopolymer

N/A

-

-

-

< 2*

PTBMA

Homopolymer

N/A

0%

4,240

3,960

1.28 (0.01)

PMAA

Homopolymer

N/A

100%

2,570

2,400

1.28

0% B

Block Copolymer

3.1:1

0%

9,320

13,200 (384)

1.13 (0.01)

PTBMA-40

Homopolymer

N/A

40%

3,640

3,380

1.28

50% B

Block Copolymer

3.1:1

50%

8,620

12,500

1.20 (0.04)

80% B

Block Copolymer

3.1:1

80%

8,250

11,700

1.29 (0.01)

0% S

Statistical Copolymer

2.7:1

0%

7,090

11,000 (442)

1.27 (0.05)

80% S

Statistical Copolymer

2.7:1

80%

6,240

10,200

1.28 (0.01)

* Vendor data
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Table 4-2

Polymers used for Evaluation of Targeted Polymer Analysis

Polymer
Name

Functional
Group

Number of
Functional
Groups

Chain
Length

Number
of MA
Units

Number
of PEG
Units

MA/PEG
Ratio

PEG
Chain
Length

Molecular
Weight

P1-Pro

-

-

18.4

15.9

2.5

6.5

1,100

5,200

P1

-

-

18.4

15.9

2.5

6.5

1,100

4,300

P1-N

NAEM

-

18.4

15.9

2.5

6.5

1,100

6,200

P1-L

CREKA

2.3

18.4

15.9

2.5

6.5

1,100

9,300

P1-H

CREKA

6.7

18.4

15.9

2.5

6.5

1,100

14,400

P1-S

CAERK

2.4

18.4

15.9

2.5

6.5

1,100

9,300

P2-Pro

-

-

18.2

16.0

2.2

7.3

300

3,100

P2

-

-

18.2

16.0

2.2

7.3

300

2,200

P2-N

NAEM

-

18.2

16.0

2.2

7.3

300

4,200

P2-L

CREKA

2.4

18.2

16.0

2.2

7.3

300

7,300

P2-H

CREKA

7.4

18.2

16.0

2.2

7.3

300

12,800

P2-S

CAERK

2.4

18.2

16.0

2.2

7.3

300

7,300

P3-Pro

-

-

30.9

26.7

4.2

6.4

1,100

8,700

P3

-

-

30.9

26.7

4.2

6.4

1,100

7,300

P3-N

NAEM

-

30.9

26.7

4.2

6.4

1,100

10,500

P3-L1

CREKA

2.2

30.9

26.7

4.2

6.4

1,100

14,800

P3-H

CREKA

6.2

30.9

26.7

4.2

6.4

1,100

21,000

P3-S

CAERK

2.2

30.9

26.7

4.2

6.4

1,100

14,800

P4-Pro

-

-

22.1

17.5

4.6

3.8

300

4,300

P4

-

-

22.1

17.5

4.6

3.8

300

3,300

P4-N

NAEM

-

22.1

17.5

4.6

3.8

300

5,400

P4-L

CREKA

2.3

22.1

17.5

4.6

3.8

300

8,700

P4-H

CREKA

7.1

22.1

17.5

4.6

3.8

300

14,200

P4-S

CAERK

2.3

22.1

17.5

4.6

3.8

300

8,600

PMAA-Pro

-

-

18.3

18.3

0.0

N/A

N/A

2,600

PMAA

-

-

18.3

18.3

0.0

N/A

N/A

1,600

PMAA-N

NAEM

-

18.3

18.3

0.0

N/A

N/A

3,800

PMAA-L

CREKA

1.9

18.3

18.3

0.0

N/A

N/A

5,800

PMAA-H

CREKA

5.8

18.3

18.3

0.0

N/A

N/A

10,800

PMAA-S

CAERK

2.0

18.3

18.3

0.0

N/A

N/A

7,800
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CHAPTER 5. BLOCKADE OF NON-SPECIFIC PROTEIN ADSORPTION AND
CELLULAR ATTACHMENT WITH UNTARGETED POLYMERIC BIOMATERIALS

Based on studies published in:
John M Medley, Eric J Beane, S K C Sundararaj, Eugene Kaplan, David A Puleo,
Thomas D Dziubla. “Block copolymers for the rational design of self-forming
postsurgical adhesion barriers.” Acta Biomaterialia, 2010, 6 (1): p. 72 [5]. Used
with permission.

5.1.

Introduction
Following abdominal surgery, the internal wound healing process can result in

fibrous tissue deposits that connect adjacent tissues, leading to the formation of postsurgical adhesions[1, 2]. While often asymptomatic, these post-surgical adhesions (PSAs)
can lead to serious problems, including bowel obstructions, chronic pain, and infertility.
In the United States, an estimated 440,000 adhesiolysis surgeries are conducted annually
to correct issues arising from the formation of PSAs [3, 4].
Of all the strategies used to prevent PSA formation, physical barriers have been
the most successful [5]. While solid barriers are often employed (such as hyaluronic acid
derivatives), some success has been demonstrated with liquid materials such as
polyethylene glycol (PEG) and phospholipids [4, 6-11]. In order to obtain next generation
improvements upon this technology, the limiting factors must be overcome, including (1)
inability to identify pro-adhesive sites, (2) general difficulty in barrier application, and (3)
limited applicability to laparoscopic surgeries. These pro-adhesive sites are often
characterized by denuded basement membrane or other damaged tissues and fibrin
exudates, which can contain highly adhesive, positively charged domains. It is
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hypothesized that an aqueous polymer solution, which can naturally target these proadhesive sites and form a barrier, will inhibit PSA formation. Adhesion formation occurs
when the fibrin gel matrix (FGM) bridges apposing tissues and remains in place,
providing a scaffold for subsequent scar formation [12-15]. By retarding protein
adsorption and cellular attachment at damaged sites, it is believed that the rate of FGM
thickening will decrease, while the rate of fibrinolysis will remain unchanged. This
should prevent the FGM from remaining in place long enough to promote PSA formation
and therefore should allow normal healing to occur at the site of damaged tissues.
Although the mechanism of interaction with the damaged tissues is different,
investigation of similar materials with a positive charge has shown promising results in
the prevention of PSAs [5, 16].
To design a material for testing this hypothesis, it is necessary to develop clear
structure-function relationships to optimize polymer barrier performance. In this work, a
living polymerization scheme and a data-rich analytical method were developed to obtain
these molecular structure-function relationships, allowing for the further development of
targetable post-surgical adhesion barriers. Group Transfer Polymerization (GTP) was
used to synthesize copolymers of methacrylic acid (MA), t-butylmethacrylate (TBMA),
and poly(ethylene glycol-methacrylate) (MN=1100, PEGMA1100) with well controlled
structures for investigation as adhesion barriers. The reaction scheme was designed to
facilitate precise control of the molecular weight and charge density of the final polymer.
Methacrylic acid was selected as the monomer for the polymer backbone due to its
demonstrated biocompatibility in a variety of applications and future amenability towards
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functionalization [17-20]. PEG was used to inhibit protein-interaction with the adsorbed
polymer layer [21-26].
Rapid, quantitative relationships between polymer properties and function were
obtained using quartz crystal microgravimetry with dissipation (QCM-D) coupled with
kinetic analysis. From this analysis, it was found that these materials adsorb rapidly to
charged surfaces and reduce subsequent non-specific protein adsorption. Depending on
the molecular architecture and charge density of the polymer, this polymeric material
exhibited up to an 81% reduction in bovine serum albumin (BSA) adsorption. The
existence of two competing mechanisms for polymer adsorption, as observed in both
energy dissipation analysis from the QCM-D and with variable angle spectroscopic
ellipsometry (VASE), provides an unanticipated means to control the adsorption of these
materials to surfaces. The protective properties of charge-targeted polymers were
confirmed with an in vitro assay of cell-substrate binding. It is anticipated that further
understanding of the adsorption mechanisms will allow the rational development of
polymeric biomaterials for the prevention of PSAs.
5.2.

Materials and Methods

5.2.1.

Quartz Crystal Substrate Preparation
A model surface consisting of amine terminated self-assembled monolayers

(SAM) on gold-coated quartz sensor crystals (Q-Sense) was employed for the evaluation
of surface adsorption and protein resistance effects. These SAM surfaces were generated
immediately prior to testing using a modification of previously described techniques
[201-203]. Prior to SAM formation, crystals were cleaned by immersion in an ammonium
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peroxide solution for 5 minutes at 70 oC, rinsed with deionized water, and dried under a
stream of inert gas [204]. Immediately after cleaning, the crystals were immersed in vials
in alkaline 1 mM 11-amino-1-undecanethiol, purged with argon, sealed, and protected
from light. After allowing the SAM formation to proceed overnight, the crystals were
removed from the solution, rinsed repeatedly with neutral ethanol and acidic ethanol, and
dried with a stream of inert gas.
5.2.2.

QCM Analysis
The functional properties of the materials were evaluated by monitoring the

sequential adsorption of the polymers and BSA to model surfaces. This technique takes
advantage of the fact that the resonant frequency of a quartz crystal varies as mass is
adsorbed onto the surface. By monitoring the resonance frequency of the crystal as it is
exposed to a series of solutions containing analytes of interest, it is possible to observe
the adsorption of nanogram scale changes in mass. All experiments were conducted in a
Quartz Crystal Microbalance (Q-Sense E4) using standard Teflon® and Tygon® tubing
materials with a flow rate of 250 µL/min. After installing a crystal in the flow module,
the sensor crystal was rinsed sequentially with acidic ethanol, neutral ethanol, deionized
water, and PBS solution to ensure that all unbound aminothiol was removed from the
crystal and to establish a flat baseline (less than 0.25 Hz/min drift). The change in
frequency and energy dissipation were measured as a function of time to monitor the
adsorption of the polymer from solution (1.0 mg/mL in PBS).
A typical experimental QCM-D curve is presented in Figure 5-1. First, a polymer
solution was flowed over the crystal surface, resulting in a decrease in resonance
frequency until saturation of the surface was achieved. After this saturation point was
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obtained, a pure buffer solution was flowed over the crystal to remove the “loosely”
bound polymer fraction. To test the barrier function of the adsorbed polymer layer, a
solution of BSA was then flowed over the surface until saturation was obtained.
Following the saturated binding, a final pure buffer solution was flowed to calculate the
amount of BSA strongly adsorbed onto the surface. Using the Sauerbrey model, which
neglects viscous effects and assumes that the adsorbed layer is rigid, the mass of
adsorbed layer was calculated using Equation (5-1). In this expression, C is a constant
characteristic of the Q-Sense E4system (17.7 ng/cm2 Hz), and n is the number of the
harmonic overtone being considered [205]. Since the change in energy dissipation was
small in all measurements (<1*10-6 per 10 Hz frequency change), the Sauerbrey model
was assumed to provide an accurate description of the adsorbed mass for all analyses
with the usual caveat that the QCM measurement also includes any water bound or
coupled to the surface [206]. A representative curve of specific mass adsorption is shown
in Figure 5-2.

Δm = −

C∆f

(5-1)

n

A simple kinetic model of the adsorption and desorption phenomena was
employed to compare the kinetics of the interactions of the materials with model surfaces.
If it is assumed that there are a discrete number of uniform surface sites available for
reversible adsorption from solution, it is possible to visualize the adsorption phenomenon
as shown in Figure 5-3. If it is further assumed that no interaction occurs between
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adsorbed molecules or between molecules on the surface with molecules in solution, this
Langmuir-type adsorption can be described by Equations (5-2) – (5-6):

[SA] =

α
β

�1 − e−βt �
α

[SA]max =
β
t 1� =
2

ln (2)

(5-2)
(5-3)
(5-4)

β

α = k1 [A][S]0

(5-5)

β = k1 [A] + k 2

(5-6)

In these expressions, [SA] is the concentration of adsorbate on the surface,
[SA]max is the maximum observed concentration observed, t½ is the half-life of the
adsorption process, [A] is the solution concentration of the adsorbate, [S]0 is the total
number of surface sites, and k1 and k2 are the kinetic coefficients of adsorption and
desorption, respectively. Using a least squares analysis, these equations were fit to the
experimental data, and [SA]max and t½ were evaluated for each adsorption event. The
observed data follow this model very closely for all of the materials examined, with the
notable exception of EPC. This material exhibited linear kinetics with no maximum
adsorption; as a result, the kinetic half-life was not determined for this material.
Since material was often observed desorbing from the surface after switching
back to a buffer solution, this desorption event was also modeled as shown in Figure 5-4.
Since [A] is equal to zero in this case, this desorption phenomenon is described by
Equations (5-7) – (5-8):
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[SA] = [SA]loose �e−k 2 t �
t 1� =
2

ln (2)
k2

(5-7)
(5-8)

The amount of material strongly bound to the surface, [SA]bound, is taken as the
difference in the amount initially adsorbed, [SA]max, and the amount observed desorbing,
[SA]loose.
This analysis assumes a perfect laminar flow over the crystal surface. Although
the flow chamber was designed to provide a very rapid exchange of solutions with
minimal mixing, there is a brief induction period when the observed kinetic rate may be
retarded by mixing within the flow cell [207]. At a flow rate of 250 µL/min and a
chamber volume of 40 µL, this induction time is 10 seconds. While this limits our ability
to obtain absolute kinetics in very fast processes, relative kinetic behavior could still be
obtained.
5.2.3.

Variable Angle Spectroscopic Ellipsometry
Gold QCM crystals were prepared using the same protocol for SAM formation

and polymer adsorption and subjected to variable angle spectroscopic ellipsometry
(VASE) using the M-2000V variable angle spectroscopic ellipsometer (J. A. Woolam
Co.). Wavelengths from 370 nm to 1700 nm were measured at 45o to 75o in 5o
increments. Data was analyzed using the WVASE32® software package in a stepwise
fashion. First, a bare gold substrate was analyzed to determine the optical constants (n
and k). Then, the amine terminated SAM was measured and the data fitted as a Cauchy
film to determine the film thickness. Finally, the polymer samples were measured. Using
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the previously fitted valued from the substrate and the SAM layer, the thickness of the
polymer layer was fitted as an additional Cauchy layer [208].
5.2.4.

Cell Attachment Studies
In order to test the anti-cellular adhesive properties of these materials, a

complementary cell culture study was carried out using the mouse mesenchymal D1 cell
line (ATCC CRL-12424) in 24-well tissue culture plates. This pluripotent cell line was
selected due to its strong adherence to charged surfaces and wound healing components
(e.g., collagen I and fibrin) [209-212]. Wells were coated with poly(L-lysine) (250 µL 0.1
mg/mL in sterile PBS) and incubated at room temperature for 2 hours. After rinsing the
wells 3 times with sterile PBS, polymer solutions were added (200 µL 1.0 mg/mL in
sterile PBS) and incubated at room temperature for 2 hours. The polymer solutions were
removed from the wells, and each well was rinsed 3 times with sterile PBS. Finally, each
well was seeded with 250,000 cells in Dulbecco’s Modified Eagle Medium (DMEM,
HyClone Laboratories) containing 10% fetal bovine serum (GIBCO/Invitrogen) and
incubated at 37 oC for two hours. Untreated tissue culture polystyrene (TCP) and PLLcoated TCP were employed, and a minimum of 6 replicates were studied for each
material.
After incubation, unattached cells were removed from the wells by rinsing twice
with sterile PBS. Representative images of the cells were obtained using an inverted
phase contrast microscope. The cells remaining on the surface after rinsing were lysed by
sonication in high salt solution (0.05 M NaH2PO4, 2 M NaCl, and 2 mM EDTA). DNA
contents, measured using Hoechst 33258 stain, were used to quantify the number of cells
in each well [213-214]. In short, Hoechst 33258 (final concentration, 0.5 µg/ml, Sigma)
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was allowed to react with lysates in the dark for 10 minutes, after which fluorescence was
measured (λ ex = 356 nm and λ em = 458 nm). An exponential calibration curve was
prepared using samples with known cell counts (0 – 200,000 cells). After measuring the
fluorescence of each well, this calibration was employed to determine the number of cells
attached in each well. Sample wells whose fluorescence indicated > 250,000 cells were
neglected as spurious measurements, since such readings would correspond to greater
than 100% cellular attachment.
5.2.5.

Statistical Evaluation
Statistical relevance was determined by performing analysis of variance followed

by a Sidak pair wise post-hoc analysis using Minitab 15. Differences at greater than 90%
and 95% confidence are reported, with statistical significance being considered at the
95% level.
5.3.

Results

5.3.1.

Polymer Binding and Release from Amine-terminated SAM Surfaces
Based upon analysis of attachment rates (on rates) of polymer adsorption (Figure

5-5), there was no statistical difference among the polymer samples. While the on rates
varied greatly between runs, detachment rates (off rates) were much more consistent. As
the fraction of acidic groups in the polymer increased from 0% to 80% for the PAA
copolymers, polymer adsorption to the charged surface varied from 211 – 468 ng/cm2
(Figure 5-6). A statistically significant maximum in [SA]max was found at a charge
density of 50%. The 40% deprotected PTBMA showed significantly less specific mass
adsorption that the 50% block copolymer. As PBS was flowed over the surface and
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polymer desorption occurred, sample differences between all charged diblock polymers
were attenuated. PAA, 40% deprotected PTBMA, and 0% deprotected block copolymer
possessed the lowest degree of surface coverage.
There was also a noticeable difference in the mechanism of binding. Figure 5-7
shows plots of the energy dissipation change (∆ D) versus the mass adsorbed. The slope
of these curves increased with charge density for the PAA copolymers. The final values
∆D

of the ratio, �∆m �), shown in Figure 5-8, provide a means to evaluate the conformation of

the polymer adsorbed to the surface [207, 215]. A lower value indicates a relatively small
amount of energy dissipation per unit mass, while a higher value reflects increasing levels
of energy dissipation per unit mass. A low value indicates a relatively rigid, compact
adsorbed layer, while a higher value for this ratio indicates an adsorbed layer that extends
further away from the surface [207].
5.3.2.

Surface Film Thickness
Variable angle spectroscopic ellipsometry was performed to verify the mass

absorption trends observed by QCM. The results of the VASE analysis are presented in
Figure 5-9. By measuring multiple wavelengths and angles, it was possible to probe the
surface multiple times and obtain an accurate measurement of the film thickness. The
PAA polymer exhibited a thickness of 109.3 Å, while the hydrophobic block copolymer
and the EPC film thicknesses were 80.5 Å and 48.4 Å, respectively. The remaining
materials showed ellipsometric thicknesses of 1.4 Å to 30.8 Å. Due to the high degree of
variance in the data, no statistically significant differences were identified.
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5.3.3.

Blockade of Protein Adsorption by Diblock Copolymers
Unlike with polymer adsorption, there was a distinct change in kinetics of protein

binding among samples (see Figure 5-10). The half-life of protein adsorption was lowest
for the surfaces with relatively hydrophobic coatings (PMAA, EPC, PTBMA-40) and for
the uncoated SAM surface, suggesting the greatest affinity of BSA. The more hydrophilic
PMAA copolymers and PAA control possessed the slowest binding rates of all materials
tested. There was no statistical difference in the kinetics of the protein adsorption for
diblock copolymer coated surfaces. As expected, the uncoated charge surface possessed
the greatest degree of protein binding (Figure 5-11). Of all test samples, 0% block
copolymer possessed the best blocking ability of all tested polymers (Figure 5-12). It is
possible that the 80% statistical copolymer sample possessed equivalent surface blocking
capacity; however, variability in the data makes this analysis inconclusive. As specific
and non-specific protein adsorption interactions are integral precursors to the formation
of a post-surgical adhesions, it is believed that the ability to delay this event serves as one
measure of a material’s ability to interrupt PSA formation.
5.3.4.

Suppression of Cellular Attachment to PLL Coated Surfaces by Diblock
Copolymers
Measurement of cell attachment was used to determine whether previously

observed differences in polymer binding to surfaces and protein adsorption to polymers
translate to reduced cell-surface interactions. In order to make meaningful comparisons
with the QCM data and to mimic the positively charged basement membrane, PLL was
used as a control surface. Close observation of the wells revealed significant
heterogeneity and pooling of cells in the well edges, suggesting that inadequate washing
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was used to remove all unbound cells. Representative images of the wells, taken from the
same location in each well, are shown in Figure 5-13. TCP and PLL mediated the
greatest level of cell attachment, with nearly full surface coverage noted. The PAA, 0%
block, EPC, PTBMA-40, and 80% block each appeared to have a slightly lower level
cellular attachment than the controls.

The 50% block, PMAA, and 80% statistical

copolymer treated wells demonstrated a large reduction in the apparent number of cells
attached during the 2 hour incubation period.
Quantitative results for cell attachment are shown in Figure 5-14. Due to the
wide variability contributed by one outlier, no statistically significant differences were
observed. Some trends, however, were observed. When copolymers possessed a negative
charge, i.e., 50% block, 80% block, and 80% statistical, suppression in cellular
attachment, compared to PLL controls, was observed.
5.4.

Discussion
In order for a material to be applicable for use as a prophylactic PSA treatment,

several requirements must be met. First, the material must be amenable to use within the
body, including biodegradability and renal clearance capacity. PEG and PMAA both
have well characterized biocompatibility and are not expected to cause adverse
biochemical interactions. Using GTP, it is possible to synthesize copolymers of PEG and
PMAA with precisely controlled molecular composition. This polymerization technique
also facilitates the synthesis of block copolymers to control the spatial orientation of the
adsorbing and protective moieties within the molecule. Relying on ester bonds to attach
the pendant PEG groups to the PMAA backbone, these materials are designed to be
susceptible to both enzymatic and hydrolytic degradation. To ensure ultimate elimination
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of the polymer, the maximum molecular weight of the synthesized materials was
designed to be less than 50 kDa [134, 216].
The primary method to assess PSA prevention technologies has been through the
use of animal models [5, 217]. Since these studies are costly, time consuming, and have
ethical implications, it is desirable to test materials in vitro prior to initiation of animal
studies.

QCM-D analysis of polymer and protein interactions with model surfaces

provides a data-rich method of analysis, affording data on polymer surface affinity,
barrier stability and performance, and absorbed layer rigidity and thickness. The simple
amine-terminated SAM model surface allows a reproducible, high throughput method to
assess these materials, aiding in the development of the method, and providing a platform
for testing the charge based targeting of the diblock poly(methacrylic acid) copolymers.
Such a system provides the opportunity for rapid evaluation and optimization during
further investigations of potential barrier materials.
The power of this method was realized upon the observation of multiple surface
adsorption mechanisms occurring as a result of changes in polymeric charge density. In
these experiments, the materials with higher concentrations of acidic groups led to a
thicker, more loosely bound layer adsorbed to the substrate. This was likely a result of the
negatively charged acid groups strongly interacting with the positively charged surface
and the grafted PEG block being forced into a more extended conformation from the
surface. As charge density decreased, a second adsorption mechanism was observed.
Although the exact nature of the interactions is unknown at this time, it is believed that
they result either from hydrogen bonding between the charged surface and PEG chains or
from hydrophobic interactions of the uncharged polymer with domains of imperfect SAM
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formation that result in the exposure of aminothiol chains to the solution. Both of these
proposed mechanisms would result in the development of a more tightly bound polymer
layer as multiple points of the polymer chain interact with the surface. This is likely to
result in a much more random adsorption to the surface with PEG chains in a less brushlike conformation. The phospholipids, which are expected to form a lamellar structure,
also form a loosely bound surface layer.
As has been observed in numerous studies, QCM cannot distinguish between
adsorbed polymer mass and polymer mass plus bound water [218-220]. In order to
determine the mass of bound water in the adsorbed layer measured by QCM, the values
obtained from QCM were compared with the results obtained from VASE. Assuming a
nominal polymer density of 1.1 g/cm3, the amount of water bound in the surface layer can
be estimated. The surface layers formed by the most hydrophilic copolymers (50% block,
80% block, and 80% statistical) contain in excess of 90% water. The more hydrophobic
materials (PTBMA-40, 0% block copolymer, and EPC) form surface layers with
approximately 50% water. These observations support the two mechanisms of surface
adsorption and surface conformation. The PAA layer indicated a greater surface mass
when measured by ellipsometry and, coupled with the high standard deviation associated
with this measurement, suggests a high degree of non-uniformity and variability within
the PAA surface film.
The most surprising finding of this work was the performance of the hydrophobic,
protected polymers. These materials possessed the lowest degree of polymer binding, but
they had the best ability to block subsequent BSA adsorption in the QCM-D analysis.
The two competing mechanisms observed during polymer adsorption can explain the
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unexpectedly strong performance of the t-butyl protected polymer. While adsorption to
the surface via electrostatic interactions was not possible, the multiple points of
interaction between the polymer and the surface resulted in a compact layer of strongly
bound material. This material occupies sites where BSA binding would potentially occur
and therefore effectively prevented nonspecific adsorption of proteins to the surface.
Indeed, this result was found to be a unique feature of the QCM-D and not replicated in
the cell culture studies, where the 0% hydrolyzed polymer possessed no ability to inhibit
cellular attachment to PLL.

The complex, multicomponent makeup of cell culture

medium compared to BSA-only solutions may explain this apparent discrepancy.
No significant differences were observed between the performances of the
statistical and block copolymers. It may be expected that the bifunctional composition of
the block copolymer would result in stronger binding to the model surface and an
increase in the extended character of the PEG moieties. These differences in polymer
architecture, however, have no significant impact on the amount of polymer adsorbed to
the model surface or the kinetics of adsorption. This suggests that, when electrostatic
forces exist, they dominate polymer-surface interactions. In addition, the fact that the
rigidity of the adsorbed layer and its ability to resist protein adsorption was independent
of the configuration of the monomeric units comprising the polymer (i.e., block vs.
statistical copolymer) suggests that protein-resistant conformation can be achieved
without a high relative concentration of PEG units.
It appears that there is a point at which both of these proposed mechanisms
contribute significantly to the adsorption of polymer. The 50% deprotected block
copolymer exhibited a statistically significant increase for material initially adsorbed to
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the surface, but upon rinsing with PBS, this difference was no longer seen. Consideration
of this observation and of the protein blockade properties that closely mimic the more
highly charged species suggests that, after an initial competition between the two binding
mechanisms, a conformation based on charge affinity was obtained. This hypothesis can
be tested by varying the pH of the adsorption conditions and determining the relative
contributions of the competing mechanisms. It is anticipated that, once more thoroughly
understood, these competitive mechanisms may be exploited to provide an additional
measure of control over the polymer properties.
The PAA control used in these experiments demonstrated a unique property that
results from the absence of PEG groups. While this polymer rapidly formed a strongly
bound surface layer, its thickness suggests that, rather than forming a molecular
monolayer on the surface, multiple layers of molecules were deposited. The resulting
layer inhibited protein adsorption kinetics, as the BSA molecules were forced to permeate
this more viscous PAA layer in order to bind to the surface. PMAA and PTBMA-40 form
similar surface layers; but, due to their increased hydrophobicity, do not retard the
adsorption of BSA.
In cell culture, when in the presence of competing negatively and positively
charged serum proteins, which could detach the bound polymer, in vitro studies
confirmed that the synthetic copolymers can bind to positively charged substrates and
significantly reduce cellular attachment. The results of the cell culture studies suggest
that the 50% block and 80% statistical copolymer were most effective, while QCM data
indicated the largest protein blockade with the 0% block and 80% statistical copolymers.
It is believed that this discrepancy results from the nonspecific binding mechanism of the
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0% block copolymer to the surface, which is incapable of suppressing cellular attachment
in more complex serum-containing solutions. As indicated by the cell attachment studies
PMAA, PTBMA-40, PAA and EPC all failed to inhibit cell attachment. Indeed, these
materials likely only exchanged the surface charge from positive to negative, and the
pluripotent mesenchymal cells can adhere to both of these charges [209, 212]. This result
is of paramount importance when designing a material that can suppress tissue adhesion.
While the proliferation of cells like the mesenchymal D1 cells are desired in wound
healing, they serve as an easy to use reference for strong cell adhesion. By designing a
material that can suppress all cells types from attaching to the surface of a damaged
organ, it is believe that more time would be allowed for sub surface wound healing to
occur, allowing for island implantation and reformation of the epithelial layer without
permitting scar tissue bridging. Future in vivo studies will be needed to verify this
hypothesis.
5.5.

Conclusion
Group transfer polymerization was successfully employed to create block

copolymers with varying charge density. The polymers adsorbed strongly to model SAM
surfaces via two competing mechanisms; the relative importance of each of these
mechanisms is a function of the charge density along the final polymer backbone. The
resulting self-formed polymer layer strongly resisted non-specific protein adsorption and
may be exploited to develop a new treatment strategy for the prevention of post-surgical
adhesions. The control afforded by the polymerization method of these synthetic
materials allows their properties to be tailored to optimize their function. Additional
investigations will focus on developing a deeper understanding of the mechanism and
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thermodynamics of the observed polymer adsorption phenomena as we move to more
biologically relevant model surfaces and confirm the relationship observed with
appropriate in vivo models of surgical adhesion formation.
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Figure 5-1

Raw data (frequency response) from QCM measurement.
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Figure 5-2

Specific mass adsorption based on Sauerbrey model, which assumes a
linear fit between frequency response and adsorbed mass.
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Figure 5-3

Kinetic fit of BSA adsorption to model substrate after preadsorption with
80% block copolymer.
[SA]max = 152.1 ng/cm2 and t½ = 20.9 s.
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Kinetic model fit of BSA desorption from model substrate after
preadsorption with 80% block copolymer.
[SA]0 = 21.9 ng/cm2 and t½ = 27.8 s.
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Figure 5-5

Polymer adsorption kinetics.
No significant differences was noted in the half-life for polymer
adsorption (grey bars) and desorption (white bars) from solution onto the
QCM surface.
* PTBMA-40 was prepared at 1.0 mg/mL, but was only partially
soluble. Insoluble material was removed by filtration and the saturated
PTBMA-40 solution was used for analysis.
** Insufficient PAA data for meaningful comparison.
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Figure 5-6

Maximum specific mass adsorption, [SA]max, and specific mass of tightly
bound polymer, [SA]bound.
Statistical comparisons are given: 90% confidence compared to 0 B (a),
95% confidence compared to 0 B (b), 95% confidence compared to
PTMBA-40 (d), 90% confidence compared to 50 B (e), 95% confidence
compared to 50 B (f), 90% confidence compared to PAA (h), and 95%
confidence compared to 80 B (n). (n = 3 – 5, M ± SE)
* PTBMA-40 was prepared at 1.0 mg/mL, but was only partially
soluble. Insoluble material was removed by filtration and the saturated
PTBMA-40 solution was used for analysis.
** Insufficient PAA data for meaningful comparison.
† EPC exhibited linear kinetics with no desorption. The mass reported is
the mass adsorbed to the surface after 200 s of adsorption in QCM.
Not included in statistical analysis.
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Figure 5-7

Dissipation change as a function of adsorbed mass for polymer adsorption
phenomena.
The slope of the curve represents the relative rigidity of the adsorbed
layer, with a steeper slope indicating a less rigid adsorbed layer.
* PTBMA-40 was prepared at 1.0 mg/mL, but was only partially
soluble. Insoluble material was removed by filtration and the saturated
PTBMA-40 solution was used for analysis.
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Figure 5-8

Terminal value of the of the energy dissipation change versus adsorbed
mass.
The observed trend indicates that, as the charge density along the polymer
increases, the polymer extends farther from the surface, indicating a more
extended PEG conformation. Statistical comparisons are given: 95%
confidence compared to 0 B (b), 95% confidence compared to PTMBA-40
(d), 90% confidence compared to 50 B (e), and 95% confidence compared
to 50 B (f). (n = 3, M ± SE)
* PTBMA-40 was prepared at 1.0 mg/mL, but was only partially
soluble. Insoluble material was removed by filtration and the saturated
PTBMA-40 solution was used for analysis.
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Figure 5-9

Film thickness measured by variable angle spectroscopic ellipsometry.
No significant differences were observed.. (n = 2 – 3, M ± SE)
* PTBMA-40 was prepared at 1.0 mg/mL, but was only partially
soluble. Insoluble material was removed by filtration and the saturated
PTBMA-40 solution was used for analysis.
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**
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Kinetics of BSA adsorption from solution.
Unlike polymer adsorption, half-life for polymer adsorption possessed
statistically significant differences suggesting a change in the kinetic
accessibility of protein to the material surface. Statistical comparisons are
given: 90% confidence compared to 50 B (e), 90% confidence compared
to PAA (h), 95% confidence compared to PAA (i), 95% confidence
compared to 80B (n). (n = 3 – 5, M ± SE)
* PTBMA-40 was prepared at 1.0 mg/mL, but was only partially
soluble. Insoluble material was removed by filtration and the saturated
PTBMA-40 solution was used for analysis.
** Insufficient NP, PMAA, and PTBMA-40 data for meaningful
comparison.
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c,p

Mass of BSA adsorbed from solution.
All polymers possessed an ability to reduce the level of protein adsorption
as determined by maximum specific mass adsorption,[SA]max, and specific
mass of tightly bound polymer,[SA]bound.
Best blockage was achieved by the uncharged diblock copolymer.
Statistical comparisons are given: 90% confidence compared to 0 B (a),
95% confidence compared to 0 B (b), 95% confidence compared to
PTMBA-40 (d), 90% confidence compared to NP (o), and 95% confidence
compared to NP (p). (n = 3 – 5, M ± SE)
* PTBMA-40 was prepared at 1.0 mg/mL, but was only partially
soluble. Insoluble material was removed by filtration and the saturated
PTBMA-40 solution was used for analysis.
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Percent protein blockade compared to control.
Statistical comparisons are given: 90% confidence compared to 0 B, 90%
confidence compared to NP (o), and 95% confidence compared to NP (p).
(n = 3 – 4, M ± SE)
* PTBMA-40 was prepared at 1.0 mg/mL, but was only partially
soluble. Insoluble material was removed by filtration and the saturated
PTBMA-40 solution was used for analysis.
** Insufficient PMAA and PTBMA-40 data for meaningful comparison.

95

Figure 5-13

Cell attachment to polymer-coated surfaces.
Representative images were obtained after incubating for 2 hours, after
which nonadherent cells were removed.
* PTBMA-40 was prepared at 1.0 mg/mL, but was only partially
soluble. Insoluble material was removed by filtration and the saturated
PTBMA-40 solution was used for analysis.
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Figure 5-14

Average degree of cellular attachment relative to the PLL control.
Cell numbers were determined using a fluorometric DNA assay (n = 4 –
11, M ± SE).
* PTBMA-40 was prepared at 1.0 mg/mL, but was only partially
soluble. Insoluble material was removed by filtration and the saturated
PTBMA-40 solution was used for analysis.
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CHAPTER 6. DISRUPTION OF FIBRIN GEL MATRIX FORMATION BY
TARGETED POLYMERS

6.1

Introduction
As has been described, the fibrin gel matrix (FGM) is a critical component in the

formation of post surgical adhesions. Consisting primarily of fibrin and a mixture of
extracellular

matrix

components

including

fibronectin,

hyaluronic

acid,

glucosaminoglycans and proteoglycans, the FGM can bridge apposing tissues in the body
and lead to the formation of PSAs [1, 8, 221]. One of the main goals of this research is to
develop a material that will interrupt FGM formation and disrupt the cascade of events
that leads to PSA formation. In the previous chapter, the ability of synthetic block
copolymers to adsorb to charged surfaces and block non-specific protein adsorption was
studied.
In order to test these materials in a more biologically relevant manner, this
investigation focuses on the ability to target polymers to fibrin coated surfaces and retard
the subsequent propagation of the fibrin gel formation. By directing these barrier
materials to the site of tissue damage, these targeted materials are expected to provide
two unique advantages. First, this approach should facilitate the protection of proadhesive
sites that are difficult to identify or are inaccessible. Second, the presence of multiple
specific interactions with the damaged tissue, the resulting barriers should provide
enhanced durability over non-targeted materials.
It was hypothesized that the molecular structure can be tailored to optimize the
adsorption of polymeric biomaterials to pro-adhesive sites on the tissue surface and
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attenuate the formation of post surgical adhesions. In order to test this hypothesis, block
copolymers were synthesized with highly controlled molecular architectures. Since PEG
was incorporated into the polymer structure for its well characterized anti-adhesive
properties, the PEG structure in the polymers were varied by using PEGMA monomer
(MN = 300 and MN = 1,100). In addition, the number of PEG chains in the polymer was
varied to study the impact of total PEG content. Finally, the effect of targeting peptides in
the polymer structure was investigated by varying both nature and the number of these
units in each polymer molecule.
After completion of the experiments, the resulting data set was statistically
analyzed to assess the relative importance of these factors in the polymers’ ability to
target fibrin and to retard various aspects of FGM formation. When statistical differences
were observed in the data for an experiment, post hoc pairwise Sidak comparisons were
used to quantify these differences. Finally, multivariate linear regression was employed
to assess the impact of the changes in molecular architecture on the results and to identify
the most important factors in the polymer’s performance in each test.
In order to exhibit optimum function, the polymer system was designed to assess
three functional criteria: binding to damaged tissue, suppression of protein adsorption,
and reduction in cellular adhesion. In order to assess these functions, several techniques
were employed. Quartz Crystal Microbalance with Dissipation (QCM-D) was used to
study the kinetics and blockade of fibrinogen adsorption. The ability to retard the
propagation of the FGM was studied using a turbidity assay to assess the kinetics of FGM
formation from a fibrin-coated surface. The attachment of cells to polymer-treated fibrin
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gels was investigated and quantified using a fluorescent DNA assay to mimic the action
of macrophages during the rearrangement and strengthening phase of PSA formation.
6.2.

Materials and Methods

6.2.1.

Polymers
A total of 20 polymers, as synthesized in Chapter 4, were created for this

analysis. As shown in Table 4-2, these polymer architectures included two levels each
for the PEG chain length (MN = 300 and MN = 1,100) and the backbone chain length
(approximately 24 and approximately 42 monomer units). In addition, the impact of
peptide type (fibrin specific CREKA versus CAERK scramble) was investigated. The
number of fibrin specific CREKA units per polymer molecule was varied from 2 – 5
peptide units per molecule. Control polymers, consisting of functionalized PMAA units
without PEG grafts were included in the analysis. Finally, free peptide (both CREKA and
CAERK), as well as a commercially available phospholipid (egg phosphatidycholine,
EPC) were used as controls.
6.2.2.

Solution Preparation
Polystyrene (PS) solution was prepared by dissolving polystyrene (MN = 280,000,

Fisher, 0.5 wt. %) in toluene (Fisher). Fibrinogen solutions (13.2 mg/ml, 0.50 mg/mL,
and 0.10 mg/mL) were prepared in Tris Buffered Saline (TBS, Aldrich). Bovine Serum
Albumin (BSA, Fisher, 1.0 mg/mL) solution was prepared in TBS. Thrombin solutions
were prepared by diluting a stock thrombin solution (5 U/mL) to the desired
concentrations in TBS (2.5 U/mL and 0.1 U/mL). All protein solutions were prepared
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each day, prior to use. Polymer solutions were prepared by dissolving purified polymer in
TBS to the desired final concentration and were stored at -20 oC prior to use.
6.2.3.

Measurement of Fibrinogen Adsorption to Fibrin Coated Quartz Crystal
Our previously developed quartz crystal microbalance method was used to

monitor the ability of targeted polymers to adsorb to fibrin coated samples and to block
subsequent fibrinogen adsorption [5]. Shown schematically in Figure 6-1, this QCM
analysis was carried out in a series of steps. First, polystyrene coated quartz crystals were
prepared to promote protein adhesion. A layer of fibrinogen was allowed to adsorb to
these crystals and was subsequently activated with thrombin to form a fibrin coated
surface. After blocking nonspecific adsorption with BSA, the test material was
introduced into the sample chamber. After a rinse step, a second fibrinogen adsorption
step was carried out and the ability of the materials to suppress this fibrinogen binding
was evaluated.
6.2.3.1.

Polystyrene Substrate Preparation
Gold coated AT-cut quartz crystals with a fundamental frequency of 5 MHz

obtained from Q-Sense were used as model substrates. These crystals were spin coated
with polystyrene (PS) to create a uniform hydrophobic surface for fibrin adsorption using
modifications of a previously described procedure [222]. Prior to coating with
polystyrene, the crystals were cleaned by soaking in toluene for a minimum of two hours
and dried in a stream of inert gas. They were subsequently spin coated with a PS solution
at 2,500 RPM for 60 seconds using a Cee® 100 spin coater manufactured by Brewer
Scientific and dried at 100 oC in a vacuum oven overnight. Using the parameters
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described in Chapter 5, the thickness of the PS layer was measured using variable angle
spectroscopic ellipsometry. Five samples were analyzed and the PS layer was determined
to be 57.1 ± 8.4 nm. In order to ensure the repeatability of this surface preparation
procedure, control QCM experiments with no barrier material were conducted
periodically throughout the data acquisition and no notable differences were observed in
the rate or level of fibrinogen deposition.
6.2.3.2.

QCM-D Analysis of Fibrinogen Deposition
A schematic depiction of the QCM experiment is shown schematically in Figure

6-1. The model substrate was first coated with a saturated layer of fibrinogen and
activated with thrombin to create a surface bound fibrin layer. After blocking nonspecific protein adsorption with BSA, the surface was optionally treated with a solution
of the protective polymer. A second fibrinogen adsorption step was then conducted.
These experiments were conducted in the Q-Sense E4 at 37 oC with a flow rate of 50
µL/min. Resonant frequency shift (Δ f) and energy dissipation (D) values were collected
for the fundamental frequency and for odd harmonics (n = 1, 3, 5, 7, 9, 11, and 13) using
the low noise setting for the duration of the experiment.
After installing four crystals in parallel and verifying their quality (D < 30 ppm in
air), TBS was flowed through the system until a stable baseline was obtained. An
experiment was started with TBS flowing and, after 5 minutes, a solution of fibrinogen
(0.1 mg/mL) was introduced into the system. After exposing the crystals to fibrinogen for
15 minutes, the system was rinsed with TBS for 5 minutes. Thrombin (0.1 U/mL) was
then flowed over the crystals for 10 minutes, followed by an additional 5 minute rinse
with TBS. BSA (1.0 mg/mL) was allowed to interact with the surfaces for 10 minutes.
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After rinsing again with buffer, a solution containing the analyte of interest (0.10 mg/mL
in TBS) was introduced and allowed to flow through the system for 5 minutes. Unbound
material was washed away with TBS for 5 minutes. A solution of fibrinogen (0.10
mg/mL in TBS) was then introduced and flowed through the system for 25 minutes.
Finally, the QCM was rinsed with of TBS for 20 minutes to facilitate the removal of
unbound fibrinogen. As a control, the same procedure was followed without the addition
of polymer solution or the subsequent buffer rinse. Each material was evaluated in a
minimum of three experiments.
Following each experiment, the QCM flow cells and all tubing were flushed with
copious amounts of acidic ethanol (10% acetic acid in ethanol) followed by pure ethanol.
The inability to obtain a stable baseline with consistent results without this cleaning
process suggests the presence of residual protein or polymer in the system. The
effectiveness of this cleaning procedure was verified by performing multiple experiments
and confirming that the observed frequency and dissipation shifts were consistent.
Finally, a stream of nitrogen was used to dry the QCM-D and the crystals were placed in
a bath of toluene to remove the PS coating.
6.2.4.

Kinetic Determination of FGM Propagation using Fibrin Turbidity Assay
Previous studies have demonstrated that surface adsorbed fibrin layers formed in

this manner retain approximately five active thrombin molecules per fibrinogen molecule
after rinsing with buffer solution [223]. These surfaces, then, can react with fibrinogen
solutions to form a fibrin gel on the surface. A microplate assay was employed to monitor
the reaction of surface bound fibrin with solution phase fibrinogen after treatment with
various materials and to investigate the structure of the resulting fibrin gels [224-225].
103

6.2.4.1.

Preparation of Fibrin Gel Substrate
A Costar high binding 96-Well EIA/RIA plate was used to maximize the strength

of interaction between the fibrin gel and the microplate. In order to create a stable gel on
the surface, fibrinogen (50 µL, 2.0 mg/mL), thrombin (20 µL, 2.5 U/mL), and calcium
chloride (10 µL, 100 mM) were added to each well. The resulting gel was allowed to cure
for 5 hours at room temperature. Each well was then rinsed twice with 200 µL TBS, and
care was taken to avoid removing the fibrin gel from the surface. A solution of each
material under investigation (50 µL, 0.10 mg/mL in TBS, n = 4) was added to the wells.
6.2.4.2.

Assessment of Fibrin Gel Propagation
After treating each gel with the material under investigation, 150 µL of fibrinogen

(0.5 mg/mL in TBS) was added to each well. In order to observe the change in turbidity
with time, a Cary Win-UV UV-visible spectrophotometer was used to monitor the UV
absorbance at 350 nm for 90 minutes with an average time of 0.5 seconds using a two
minute collection interval.
6.2.5.

Cellular Attachment to Fibrin Gels
In order to test the anti-cellular adhesive properties of these materials, a

complementary cell culture study was carried out using the mouse mesenchymal D1 cell
line (ATCC CRL-12424) in 24-well tissue culture plates. This pluripotent cell line was
selected due to its strong adherence to charged surfaces and wound healing components
(e.g., collagen I and fibrin) [209-212].
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6.2.5.1.

Preparation of Fibrin Gels for Cell Culture Studies
Stable fibrin gels were created in the well plates for use as a substrate to measure

cellular attachment. Tris buffered saline was filtered through a 0.22 µm syringe filter and
solutions (13.2 mg/mL fibrinogen, 5 U/mL thrombin, and 100 mM CaCl2) were prepared
in a laminar flow hood to minimize microbial contamination. In each well, 152 µL of a
fibrinogen solution was subsequently mixed with 40 µL CaCl2 solution and 8 µL
thrombin solution to yield a solution that was 10 mg/mL fibrinogen, 20 mM CaCl2, and
0.2 U/mL thrombin. This solution was allowed to gel at room temperature for 1 hour and
was then allowed to mature overnight at 4oC.
6.2.5.2.

Cell Culture
After rinsing the wells 3 times with sterile TBS, polymer solutions were added

(200 µL, 0.10 mg/mL in sterile TBS) and incubated at 37 oC for 90 minutes. The polymer
solutions were removed from the wells, and each well was rinsed 3 times with sterile
TBS. Each well was then seeded with 250,000 cells in 500 µL Dulbecco’s Modified
Eagle Medium (DMEM, HyClone Laboratories) containing 10% fetal bovine serum
(GIBCO/Invitrogen) and incubated at 37 oC for two hours. Untreated tissue culture
polystyrene (TCP) fibrin gels with no anti-adhesion barrier were employed as controls,
and a minimum of 6 replicates were studied for each material.
After incubation, unattached cells were removed from the wells by rinsing three
times with sterile TBS. Representative images of the cells were obtained using an
inverted phase contrast microscope. The cells remaining on the surface after rinsing were
lysed by sonication in high salt solution (0.05 M NaH2PO4, 2 M NaCl, and 2 mM
EDTA). DNA contents, measured using Hoechst 33258 stain, were used to quantify the
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number of cells in each well [213-214]. In short, Hoechst 33258 (final concentration, 0.5
µg/ml, Sigma) was allowed to react with lysates in the dark for 10 minutes, after which
fluorescence was measured (λ ex = 356 nm and λ em = 458 nm). An exponential calibration
curve was prepared using samples with known DNA concentrations (0.16 – 5.0 µg/mL).
After measuring the fluorescence of each well, this calibration was employed to
determine concentration of DNA in each well. Since the duration of the experiment was
not long enough for appreciable cell growth to occur, this value was used as a measure of
the number of cells attached in each well.
6.2.6.

Statistical Analysis
For comparisons, statistical relevance was determined by performing analysis of

variance followed by a Sidak pair wise post-hoc analysis using Minitab 15. Each figure
was analyzed separately. Differences at greater than 95% and 99% confidence are
reported, with statistical significance being considered at the 95% level. Unless otherwise
stated, all values are reported as mean ± standard error.
In order to understand the impact of the molecular architecture on the various
performance parameters evaluated, an additional statistical analysis was conducted. This
modeling included the 16 block copolymers described in Table 6-1. The responses from
the QCM analysis, turbidity assay, and cellular attachment study, were included in this
analysis. For each response, ANOVA was carried out by fitting a general linear model
using the variables of PEG chain length, number of PEG units, number of monomer units
in the polymer backbone, peptide type, and number of peptide units per polymer
molecule.
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For each model, residual plots, including a normal probability plot, a frequency
plot, and standardized residual plots were generated. These plots were used to verify the
validity of the assumptions made in the general linear model. If the residuals are normally
distributed, the normal probability plot is expected to show a linear trend with minor
deviations in the tails. In addition, the frequency plot should by symmetrical with
approximately 95% of the values within the range of ± 2 [226]. Finally, no apparent bias
should be observed in the standardized residual plots [227-229]. In cases where apparent
deviations from normality were observed, the analysis was repeated after removal of
outliers to ensure that the trends predicted by model were unaffected. Main effects plots
were then generated for each model in order to understand the impact of each factor. No
outliers were removed from the analysis.
6.3.

Results
The studies conducted provided data with a wide range of responses and, in most

cases, low variability. If outliers were observed for a given model, they have been
identified. The wealth of information that was obtained from these results provides the
basis for a thorough understanding of the performance of the materials as a function of
the structure of the polymer and the number and composition of the targeting moieties. In
addition, the nature of any outliers provides insight into the limitation of the statistical
model employed and can be interpreted to provide additional mechanistic information.
6.3.1.

QCM Analysis
As can be seen in Figure 6-2, the energy dissipation observed with the fibrinogen

coated samples (Δ D = 4 – 8 x 10-6) was much greater than what was seen in SAM
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experiments (Δ D = 0.5 – 3 x 10-6, see Figure 5-7). As a result, the approximations
employed in the Sauerbrey model are not valid, and the mass adsorbed on the surface
could not be accurately determined. Instead, raw frequency response data was employed
to extract pseudo-first order parameters for the maximum fibrinogen adsorption and the
kinetic rate constant for the two fibrinogen adsorption events.
Since the goal of these studies is to assess the ability of the materials to inhibit the
adsorption of fibrinogen to a surface bound fibrin layer, two kinetic parameters are
reported. First, the maximum fibrinogen adsorption observed in the second fibrinogen
adsorption step was determined using a least squares analysis in Excel®. This value was
Fg

then normalized to the first fibrinogen response and is reported as the ratio, �Fg 2 �. In
1

addition, the pseudo-first order kinetic half-life (t½,Fib) of the second fibrinogen
adsorption step was determined using a least squares analysis in Excel®.
The data in Figure 6-3 – Figure 6-5 present the frequency response for the
materials studied. The mass of fibrinogen adsorbed in the second step was found to be
dependent upon the nature of the barrier material employed. The ratio for the control
Fg

samples with no polymer ( Fg 2 = 0.54 ± 0.05), is shown on the figures as a horizontal line
1

for reference. Statistical differences are indicated on the graphs. The P3 polymer

conjugate with the high level of peptide conjugation (P3-H), which appears to be missing
from the data, exhibited complete suppression of the second fibrinogen step in three
experiments. As a result, all frequency responses for this material are reported as zero.
Several other materials, including the peptide controls and the P4 conjugates and the
PMAA conjugates PMAA-L and PMAA-S, exhibited significant levels of inhibition of
the fibrinogen adsorption ratio. Several of the unconjugated polymers (PMAA, P2, and
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P4) increased the second fibrinogen adsorption ratio dramatically (116%, 384%, and
195%, respectively). The low level peptide conjugates of the long PEG chain polymers
(P1-L and P3-L) failed to demonstrate suppression of fibrinogen adsorption.
From the residual plots for fibrinogen adsorption, shown in Figure 6-6, it is seen
that, with the exception of two notable outliers (P2 and P4), the normal probability plot is
linear and that the residuals are normally distributed. The main effects plots, shown in
Figure 6-7, indicate that the fibrinogen ratio decreases with increasing chain length and
with increasing PEG chain length. The number of PEG chains per molecule does not
show any clear trend. The two peptides reduce the value for the fibrinogen ratio, as does
an increase in the number of peptides conjugated to the polymer.
The results of the kinetic analysis for the second fibrinogen adsorption step are
presented in Figure 6-8 – Figure 6-10. The half-life for the control samples without
polymer adsorption (t½ = 530 ± 90 s) is shown on these graphs for reference. Since no
fibrinogen was observed adsorbing to the surface for PS-3, no value is reported for this
material. While there are differences among the materials tested, only PMAA (t½ = 1330
± 160 s) and P2 (t½ = 2000 ± 280 s), demonstrated a significant difference in the kinetics
of fibrinogen absorption from the control.
The residual plots for the kinetics of fibrinogen adsorption, shown in Figure 6-11,
confirm that, with the exception of 2 outliers (both P2), the normal probability plot is
linear and the residuals are normally distributed. The main effects plots, shown in Figure
6-12, indicate that the rate of fibrinogen adsorption is not a strong function of chain
length or of the number of PEG chains. The kinetics slow with increasing PEG chain
length The two peptides appear to reduce the rate of fibrinogen deposition, as does an
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increase in the number of peptides conjugated to the polymer. Because of the relatively
thick fibrin surface film and the large size of fibrinogen compared to BSA, the fibrinogen
adsorption kinetics are slower that the BSA adsorption kinetics studied in Chapter 5 by
an order of magnitude.
6.3.2.

Fibrin Turbidity Assay
In order to assess the ability of the polymers to block the surface growth of the

fibrin matrix, a kinetic assay was performed using the data obtained from
spectrophotometry. After subtracting the initial absorbance values due to the preexisting
fibrin layer in the microplate wells, the increase in turbidity could readily be observed.
The rate of turbidity increase was approximated by fitting the initial data with a linear
equation and determining the slope of the resulting line. As shown by the data in Figure
6-13 – Figure 6-15, the value of this rate varies with the structure of the barrier material.
The TBS control exhibited a value of 0.0039 ± 0.0007 min-1. There were no significant
differences observed between the samples and the controls. Some statistically significant
differences, however, were observed among the polymer samples.
The residual plots for the kinetics of fibrinogen propagation, shown in Figure
6-16, confirm that the normal probability plot is linear and the residuals are normally
distributed. The main effects plots, Figure 6-17, indicate that the rate of fibrinogen
propagation is not a strong function of chain length or number of PEG chains. The
kinetics slow with increasing PEG chain length and with an increasing number of
peptides conjugated to the structure. The CREKA peptide appears to reduce the rate of
fibrinogen deposition, while the impact of the CAERK scramble is much less
pronounced.
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6.3.3.

Cellular Attachment
The results of the cellular attachment study, shown in Figure 6-18 – Figure 6-20,

indicate that many of the materials significantly reduced the attachment of cells to the
model fibrin surface. All of the PMAA polymers result in a significant reduction of
cellular attachment, while the majority of the long PEG chain polymers show an effect.
There were no significant differences observed with the short PEG chain polymers. As
shown in Figure 6-21, images taken of the wells indicate that the cells were not
uniformly distributed on the fibrin surface. This artifact of the cell loading procedure
made accurate visual comparisons of the cells impossible. A comparison of the TCP
versus the fibrin control wells, however, is very instructive. The fibrin control showed
normalized cellular attachment of 1.00 ± 0.09, while the TCP control had cellular
attachment values of 0.30 ± 0.09. This difference, also evident in the images in Figure
6-21, results from the greatly enhanced surface area created by the three-dimensional
network of the fibrin gel.
The residual plots for the cellular attachment to the fibrin substrate are shown in
Figure 6-22. With the exception of 1 outlier, the normal probability plot is linear and the
residuals are normally distributed. The main effects plots, shown in Figure 6-23, suggest
that the degree of cellular attachment is not function of the number of PEG units, PEG
chain length, or the number of peptide units in the structure. The presence of peptide,
both CREKA and CAERK, appears to promote cellular attachment. While no clear trend
is evident in the performance as a function of polymer chain length, the longest polymer
appears to provide enhanced resistance to cellular attachment.
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6.4.

Discussion
The quartz crystal microbalance proved to be a very informative means to study

the fibrinogen adsorption. Unlike the previous study (see Chapter 5), it was impossible
to quantify the rate or degree of polymer adsorption to the model surfaces. The presence
of the water-rich surface layer of fibrinogen resulted in high levels of energy dissipation
and is probably responsible for this inability to discern the adsorption of these barrier
materials. As has previously been described, the level of the second fibrinogen adsorption
was normalized and reported as the ratio of the second fibrinogen adsorption step to the
Fg 2

first (Fg 1). This technique was employed in order to eliminate the effect of the variability

observed in the first fibrinogen adsorption step that resulted from a degraded frequency
response as QCM crystals were repeatedly reused.
Numerous properties of targeted block copolymers have been investigated to
assess their ability to interrupt the physiological processes that lead to the formation of an
extended gel matrix. Since this FGM formation is a prerequisite to the formation of post

surgical adhesions, it is believed that the finding from these studies will be readily
extended to understand the impact on material properties to the ability to reduce PSA
formation. A summary of the effects of molecular architecture on these functional
properties, summarized in Table 6-2, reveals several important relationships that provide
insight into the mechanism of action.
The ratio of fibrinogen adsorption in the QCM-D was studied to monitor the
ability of these materials to reduce the affinity of surfaces for fibrinogen. It was
anticipated that longer PEG chains, longer polymer chains, larger PEG chain density, and
a larger density of targeted peptide units would provide increased protection against the
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adsorption of fibrinogen to surface bound fibrin layers. This prediction was confirmed in
most cases; in fact, the high molecular weight polymer with long PEG chains and a high
level of CREKA (P3-H) resulted in the complete suppression of this second fibrin
adsorption step. Compared to the rest of the polymer architectures, this structure appears
to represent an optimum balance of surface affinity (due to the high peptide content) and
protective ability (due to the long PEG chains). The difference observed between the
short polymer chain and long polymer chain is also notable. The shorter polymer chains
are much less effective at inhibiting fibrinogen adsorption, potentially as a result of the
action of the PEG groups on the peptide units. The long PEG chains can articulate and
form a hydration shell of approximately the same dimensions as the shorter polymer and
shield the attached peptide units from interacting strongly with the fibrin surface. The
longer polymer chains extend past this shell and present readily available peptide units to
the active surface.
The rate of fibrinogen adsorption, while similar for most of the materials, appears
to be slowed for the PMAA and P2 polymers. It is possible that this apparent reduction in
rate is an artifact of mass transfer limitations related to the very high level of fibrinogen
adsorbed for these materials.
Most of the polymers appear to slow the kinetics of fibrin propagation.
Unfortunately, due to the wide degree of variability in the data, very few statistically
significant differences were observed in this rate. The phospholipid (EPC), on the other
hand, appears to enhance the rate of fibrin propagation. This probably results from the
simultaneous growth of phospholipid lamella within the fibrin gel matrix structure. Since
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both of these structures can scatter light, such a mechanism would lead to the more rapid
turbidity increase.
Cellular attachment studies resulted in several interesting observations. As a result
of their highly negative charge, the PMAA polymers were surprisingly effective at
reducing the observed cellular attachment. While few statistically significant differences
were observed in the level of cellular attachment, all of the materials appear to reduce this
response compared to the untreated fibrin control. It can be deduced, then, that all of the
materials adsorb to the fibrin gel surface and can reduce cellular attachment through
either steric hindrance or charge based repulsion.
Using statistical analysis, it is possible to develop a better understanding of the
relationships between the molecular structure and the performance in these experiments.
The trends seen in the factor plots can be used to inform decisions about the development
of subsequent materials and can serve as the basis for additional mechanistic
understanding. Finally, these statistical techniques allow for the identification of potential
outliers that may lead to additional understanding of the mechanism or experimental
design.
The results obtained from the QCM experiments reveal several trends in the
ability of these materials to suppress this fibrinogen adsorption. The trends are
summarized in Table 6-2. Based on the summary data, it is possible to identify several
attributes of the polymer architecture that are important for the attenuation of post
surgical adhesion formation. The length of the PEG chains appears to be an important
determinants of performance for the materials. Neither the number of PEG chains in each
polymer molecule nor the polymer chain length appear to be major factors in assessing
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the performance. The largest impact on performance appears to arise from the peptide
units. While the number of peptide units appears to be very important, the most
unexpected results were observed when assessing the impact of the peptide type on
material performance.
For many of the experiments, the number of peptide units conjugated to the
polymer is a strong predictor of the material’s performance. In most instances, however,
the impact of the nature of the peptide was much less pronounces. This result was
particularly surprising since CREKA has been shown to be an excellent targeting moiety
for protein clots [171-173, 177]. CAERK, on the other hand, was not anticipated to show
a high affinity for fibrinogen. While polymers conjugated with CREKA and CAERK
both inhibit the degree and rate of subsequent fibrinogen adsorption and reduce the level
of cellular attachment to model surfaces, the CREKA-based materials are much more
effective at reducing the propagation of fibrin from a surface. These effects may be
attributable to differences in the precise nature of the binding epitopes for the two peptide
units. Both peptides exhibit an affinity for fibrin and can direct polymeric materials to
associate with the fibrin-coated surfaces form barriers to subsequent protein adsorption
and cellular attachment. The relative ineffectiveness of the CAERK materials at reducing
fibrin polymerization from surfaces suggests that this peptide unit competes less
effectively for the binding sites where subsequent fibrinogen polymerization occurs.
The effect of PEG chain length in each of the experiments indicates that longer
polyethylene glycol units are more likely to result in a material likely to interrupt the PSA
formation process. Longer PEG chains have been shown to result in increasing resistance
to protein adsorption, so this result agrees with previously reported observations. The
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relationship between an increase in the PEG length and a decrease in the degree and
kinetics of fibrinogen adsorption is likely a result of the increasing thickness of the
hydrated PEG layer with longer PEG chains. As this layer becomes thicker, not only does
the affinity of fibrinogen for the surface layer decrease, but mass transport limitations
through this hydrated layer suppress the rate of surface adsorption.
A similar mechanism also explains the ability of the long PEG chain materials to
protect surfaces from cellular attachment and to retard the propagation of the fibrin gel
matrix. The decrease in cellular attachment results from the inability of proteins to attach
to thick, hydrated PEG layers. The decrease in the rate of fibrin propagation may arise
from an increase in mass transport limitations due to hydrated PEG layer. In order for the
solution phase fibrinogen to polymerize and form a fibrin gel, it must be activated with
the surface bound thrombin. If this thrombin is coated with the PEG containing polymer,
the fibrinogen must diffuse through this layer to the active site. Longer PEG chains, then,
can inhibit the rate of fibrin gel propagation from the model surface more effectively than
shorter PEG chains.
Surprisingly, the number of polyethylene glycol chains per polymer molecule
does not appear to impact the fibrinogen blocking ability of the materials. Although the
level of polymer adsorption could not be directly observed in these experiments, this lack
of dependence on the concentration of PEG chains may result from the formation of a
surface layer with complete PEG coverage. Once this level of surface saturation is
achieved, further adsorption of polymers to the surface is unlikely. This knowledge may
provide a means of tailoring the durability of the surface films formed by these materials.
Since the desorption of polymers from surfaces should be first order with respect to the
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number of polymer chains on a surface, having a larger number of chains on the surface
may lead to longer lasting surface protection. Since the number of surface bound polymer
molecules appears to be indirectly related to the number of PEG chains per molecule, it
may be possible to create longer lasting surface films with similar performance properties
by forming polymers with a low number of PEG chains per molecule.
6.5.

Conclusion
The techniques employed in this study allowed for a thorough investigation of the

relationship between the structure and function for a series of targeted block copolymers.
By systematically varying multiple aspects of the molecular architecture and employing
statistical analysis to study these structure-function relationships, the complex nature of
these materials to inhibit FMG propagation were successfully probed. As was anticipated,
the function of these materials was highly dependent on the molecular architecture of the
polymer.
As expected, longer PEG chains tend to inhibit all of the potential pathways of
PSA that were modeled. While the number of PEG chains in each polymer molecule did
not appreciably affect the performance, the impact of the number of peptide units was
dramatic. In addition, the subtle differences in the performance of the two peptides
support the hypothesis that targeting can be used to direct the performance of materials to
interrupt the formation of the fibrin gel matrix and prevent the formation of post surgical
adhesions. Although the CREKA functionalized polymers functioned very well in all
tests, the CAERK scramble signaled similar efficacy in many cases. This observation
suggests that CAERK may also be an effective targeting unit for the fibrin molecule. The
relationships between the molecular architecture and performance provide valuable
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insight and form a knowledge base that can be used to inform future investigations of
biomaterials for PSA prevention.
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Fibrinogen

BSA

Fibrinogen

Thrombin

X

Figure 6-1

Schematic representation of proposed fibrin blockade mechanism in QCM
analysis.
A surface-bound fibrin film is first generated by adsorption to the
polystyrene surface and activation with fibrinogen. After blocking
uncoated surface sites with BSA, a second fibrinogen adsorption step is
carried out, and a large amount of fibrinogen is observed adsorbing to the
surface. If the initial fibrin layer is treated with a polymeric adhesive
barrier material, the amount of fibrinogen adsorbed in this second step can
be greatly reduced.
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Figure 6-2

Representative QCM sensorgram of fibrinogen suppression study.
After establishing a baseline in tris buffered saline (TBS), fibrinogen,
thrombin, bovine serum albumin (BSA), polymer, and fibrinogen
solutions were introduced into the system sequentially. As indicated by the
shaded regions, a TBS wash was employed between solution
introductions. The frequency shift (∆f, blue) and energy dissipation
change (∆D, red) were monitored continuously throughout the experiment.
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PMAA-L PMAA-H PMAA-S

Fibrinogen adsorption ratio for controls and PMAA polymers.
Values (M ± SE) represent the mass ratio seen in the final and initial
fibrinogen adsorption steps. The horizontal bar represents the ratio
observed for the control samples with no polymer treatment. Statistically
significant differences are reported: 99% compared to no polymer (b),
99% compared to PMAA (d), 95% compared to PMAA-H (e), 99%
compared to PMAA-H (f), 95% compared to EPC (g), and 99% compared
to EPC (h).
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Fibrinogen adsorption ratio for long (MN = 1,100) PEG chain polymers.
Values (M ± SE) represent the mass ratio seen in the final and initial
fibrinogen adsorption steps. The horizontal bar represents the ratio
observed for the control samples with no polymer treatment. No
absorption was observed for P3-H in the second adsorption step.
Statistically significant differences are reported: 99% compared to no
polymer (b), 95% compared to P3-H (i), and 99% compared to P3-H (j).

122

Fibrinogen Accumulation Ratio
(Fg2/Fg1)

3.0

b

2.5
b,k

2.0

1.5

1.0
l,n

l,n

l,n

0.5

l,n

l,n
l,n

22.1
CREKA
2.3
P4-L

7.1
P4-H

P4 - S

H

7.4
P2-H

N/A
0
P4

P4 -

2.4
P2-L

CAERK
2.4
P2-S

P4 - L

18.2
CREKA

P4

P2 - S

H

P2 -

Figure 6-5

N/A
0
P2

P2 - L

Polymer Chain Length
Peptide Type
Number of Peptide Units
Code

P2

0.0

CAERK
2.3
P4-S

Fibrinogen adsorption ratio for short PEG (MN = 300) chain polymers.
Values (M ± SE) represent the mass ratio seen in the final and initial
fibrinogen adsorption steps. The horizontal bar represents the ratio
observed for the control samples with no polymer treatment. Statistically
significant differences are reported: 99% compared to no polymer (b),
95% compared to P2 (k), 99% compared to P2 (l), and 99% compared to
P4 (n).
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Residual Plots for Ratio
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Residual plots for fibrinogen adsorption ratio.
The validity of the general linear model used for the ANOVA for the
fibrinogen adsorption ratio is confirmed by the residual plots. The linearity
of the normal probability plot and random distribution observed in the
standardized residual plots indicate a lack of bias in the model fit. The
histogram of standardized residuals indicates a normal distribution of
residuals. In addition, the vast majority of the residuals are within the
expected range of ± 2 standard deviations. The two outliers with
standardized residuals above 3 result from the wide variability in the data
for the short PEG chain polymers without peptide conjugation (P2 and
P4).
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Main Effects Plot for Ratio
Data Means

Chain Length

PEG Length

PEG No

1.00
0.75
0.50

Mean

0.25
0.00
18.2

18.4

22.1

30.9

Peptide Ty pe

300

1100

2.2

2.5

4.2

4.6

Peptide No

1.00
0.75
0.50
0.25
0.00
CAERK

Figure 6-7

CREKA

NP

0.0 2.2 2.3 2.4 6.2 6.7 7.1 7.4

Main effects plot for fibrinogen adsorption ratio.
The main effects plots for the ratio of fibrinogen adsorption provide
insight into the importance of the various aspects of polymer architecture
that were investigated. As indicated by the strong dependence of the
response to the number of peptide units (Peptide No) and the peptide type,
these two factors have the most influence on the performance in this
experiment. The existence of peptide units in the polymer is of critical
importance, while the impact of peptide type is unclear. More peptide
units lead to a decrease in the observed fibrinogen ratio. Increases PEG
length decrease the fibrinogen adsorption ratio, while no statistically
significant trend is evident with changes in the number of PEG groups in
each polymer molecule or in the overall chain length.
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Fibrinogen adsorption kinetics for controls and PMAA polymers.
Values (M ± SE) represent the kinetic half-life seen in the second
fibrinogen adsorption step. The horizontal bar represents the half-life
observed for the control samples with no polymer treatment. Statistically
significant differences are reported: 99% compared to no polymer (b),
99% compared to PMAA (d), 99% compared to PMAA-H (f), and 95%
compared to CAERK (o).
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Fibrinogen adsorption kinetics for long PEG chain (MN = 1,100)
polymers.
Values (M ± SE) represent the kinetic half-life seen in the second
fibrinogen adsorption step. The horizontal bar represents the half-life
observed for the control samples with no polymer treatment. No
statistically significant differences were observed.
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Fibrinogen adsorption kinetics for short PEG chain (MN = 300) polymers.
Values (M ± SE) represent the kinetic half-life seen in the second
fibrinogen adsorption step. The horizontal bar represents the half-life
observed for the control samples with no polymer treatment. Statistically
significant differences are reported: 99% compared to no polymer (b), and
99% compared to P2 (l).

128

Residual Plots for Half-Life
Normal Probability Plot

Versus Fits
Standardized Residual

99.9

Percent

99
90
50
10
1
0.1

-4

-2

0
2
Standardized Residual

4

5.0

2.5

0.0

200

Histogram
Standardized Residual

Frequency

12
8
4
-2

Figure 6-11

-1

0
1
2
3
Standardized Residual

600
800
Fitted Value

1000

Versus Order

16

0

400

4

5.0

2.5

0.0

1 5

10 15 20 25 30 35 40 45 50 55 60
Observation Order

Residual plots for the kinetic half-life of the second fibrinogen adsorption
step in QCM experiments.
The validity of the general linear model used for the ANOVA for the halflife of the second fibrinogen adsorption step is supported by the residual
plots. There are, however, two apparent outliers, both for the short PEG
chain polymer with no peptide (P2). With the exception of these outliers,
the linearity of the normal probability plot and random distribution
observed in the standardized residual plots indicate a lack of bias in the
model fit. The histogram of standardized residuals suggests a normal
distribution of residuals. Excepting the two outliers, all of the residuals are
within the expected range of ± 2 standard deviations.
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Main Effects Plot for Half-Life
Data Means
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Main effects plots for the kinetic half-life of second fibrinogen adsorption
step.
The main effects plots for the half-life of the second fibrinogen adsorption
step provide insight into the importance of the various aspects of polymer
architecture that were investigated. As indicated by the strong dependence
of the response to the peptide type this factor has the largest influence on
the performance in this experiment. The presence of peptide units in the
polymer is of critical importance, while the impact of peptide type is
unclear. Increases in PEG length and in the number of PEG units appear to
decrease rate of fibrinogen deposition. No statistically significant trend is
evident with changes in the overall chain length of the polymer or with the
number of peptide units.
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Kinetic analysis of fibrin gel propagation from fibrin surface for controls
and PMAA polymers.
Values (M ± SE) represent the initial rate of turbidity increase observed
during fibrin propagation. The horizontal bar represents the half-life
observed for the control samples with no polymer treatment. Statistically
significant differences are reported: 99% compared to PMAA (d), and
95% compared to EPC (g).
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Kinetic analysis of fibrin gel propagation from fibrin surface for long PEG
chain (MN = 1,100) polymers.
Values (M ± SE) represent the initial rate of turbidity increase observed
during fibrin propagation. The horizontal bar represents the half-life
observed for the control samples with no polymer treatment. Statistically
significant differences are reported: 95% compared to P1 (q).
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Kinetic analysis of fibrin gel propagation from fibrin surface for short
PEG chain (MN = 300) polymers.
Values (M ± SE) represent the initial rate of turbidity increase observed
during fibrin propagation. The horizontal bar represents the half-life
observed for the control samples with no polymer treatment. No
statistically significant differences were observed.
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Residual Plots for Slope
Normal Probability Plot
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Residual plots for kinetic analysis of fibrin gel propagation from fibrin
surface.
The validity of the general linear model used for the ANOVA for the
kinetic analysis of fibrin gel propagation is supported by the residual plots.
There is, however, one apparent outlier, that results from the short PEG
chain polymer with no peptide (P2). With the exception of this outlier, the
linearity of the normal probability plot and random distribution observed
in the standardized residual plots indicate a lack of bias in the model fit.
The histogram of standardized residuals suggests a normal distribution of
residuals. Excepting the outlier, all of the residuals are within the expected
range of ± 2 standard deviations.
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Main Effects Plot for Slope
Data Means
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Main effects plots for the kinetics of fibrin propagation.
The main effects plots for the kinetics of fibrin propagation provide
insight into the importance of the various aspects of polymer architecture
that were investigated. As indicated by the strong dependence of the
response to the number of peptide units (Peptide No) and the peptide type,
these two factors have the largest influence on the performance in this
experiment. The type of peptide units in the polymer is of critical
importance. No statistically significant trends were observed with changes
in the number of peptide units, PEG chain length, or overall chain length.
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Cellular Attachment
Normalized to Fibrin Control
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Normalized cellular attachment data for controls and PMAA polymers.
Values (M ± SE) represent the degree of cellular attachment, based on
DNA assay, normalized to fibrin controls. Statistically significant
differences are reported: 95% compared to no polymer (a), and 99%
compared to no polymer (b).
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Cellular Attachment
Normalized to Fibrin Control
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Normalized cellular attachment data for long PEG chain (MN = 1,100)
polymers.
Values (M ± SE) represent the degree of cellular attachment, based on
DNA assay, normalized to fibrin controls. Statistically significant
differences are reported: 95% compared to no polymer (a), and 99%
compared to no polymer (b).
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Normalized cellular attachment data for short PEG chain (MN = 300)
polymers.
Values (M ± SE) represent the degree of cellular attachment, based on
DNA assay, normalized to fibrin controls. No statistically significant
differences were observed.
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Figure 6-21

Images of cells attached to fibrin gel after treatment with barrier material.
These images (Fibrin, TCP, PMAA-S, P1-L, and P1-S, clockwise from top
left) are representative of the cells after incubation. The heterogeneous
distribution of cells in the wells made accurate visual assessment of the
cellular density impossible.

Copyright © John M. Medley 2010
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Residual Plots for Cellular Attachment
Normal Probability Plot
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Residual plots for attachment of cells to fibrin substrate.
The validity of the general linear model used for the ANOVA for the
kinetic analysis of fibrin gel propagation is supported by the residual plots.
There are, however, three apparent outliers. These outliers result from P2H, P2-S, and P3-L. With the exception of these outliers, the linearity of the
normal probability plot and random distribution observed in the
standardized residual plots indicate a lack of bias in the model fit. The
histogram of standardized residuals suggests a normal distribution of
residuals. Excepting the outliers, all of the residuals are within the
expected range of ± 2 standard deviations. The outliers potentially result
from the non-linear nature of the fluorescence assay employed for the
quantification of cellular attachment, where small experimental variation
can result in large variation in the results.
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Main Effects Plot for Cellular Attachment
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Main effects plots for attachment of cells to fibrin substrate.
The main effects plots for the attachment of cells to fibrin substrate
provide insight into the importance of the various aspects of polymer
architecture that were investigated. As indicated by the strong dependence
of the response to the presence of peptide, this factor has the largest
influence on the performance in this experiment. No trend is observed for
the response with changes in polymer chain length; however, the longest
chain length material showed a dramatic decrease in the level of cellular
attachment. No statistically significant trend was observed with changes in
PEG chain length, number of PEG chains, or number of peptide units.
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Table 6-1

Polymer
Code

Polymers Included in General Linear Model for Targeted Polymer
Analysis
Functional
Group

Number of
Functional
Groups

Chain
Length

Number
of MA
Units

Number
of PEG
Units

MA/PEG
Ratio

PEG
Chain
Length

Molecular
Weight

P1

-

-

18.4

15.9

2.5

6.5

1,100

4,300

P1-L

CREKA

2.3

18.4

15.9

2.5

6.5

1,100

9,300

P1-H

CREKA

6.7

18.4

15.9

2.5

6.5

1,100

14,400

P1-S

CAERK

2.4

18.4

15.9

2.5

6.5

1,100

9,300

P2

-

-

18.2

16.0

2.2

7.3

300

2,200

P2-L

CREKA

2.4

18.2

16.0

2.2

7.3

300

7,300

P2-H

CREKA

7.4

18.2

16.0

2.2

7.3

300

12,800

P2-S

CAERK

2.4

18.2

16.0

2.2

7.3

300

7,300

P3

-

-

30.9

26.7

4.2

6.4

1,100

7,300

P3-L1

CREKA

2.2

30.9

26.7

4.2

6.4

1,100

14,800

P3-H

CREKA

6.2

30.9

26.7

4.2

6.4

1,100

21,000

P3-S

CAERK

2.2

30.9

26.7

4.2

6.4

1,100

14,800

P4

-

-

22.1

17.5

4.6

3.8

300

3,300

P4-L

CREKA

2.3

22.1

17.5

4.6

3.8

300

8,700

P4-H

CREKA

7.1

22.1

17.5

4.6

3.8

300

14,200

P4-S

CAERK

2.3

22.1

17.5

4.6

3.8

300

8,600
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Table 6-2

Effects of Variation in Molecular Architecture on Material Performance
Response

Chain
Length

Variable

PEG Chain
Length

Fibrinogen
Adsorption Ratio
𝐅𝐅𝐠𝐠
� 𝟐𝟐�

Fibrinogen
Deposition Half-Life

𝐅𝐅𝐠𝐠 𝟏𝟏

↓

Initial Rate of
Fibrin Gel
Propagation

Cellular
Attachment

↓*
↓
↓

Number of
PEG Units
Number of
Peptide
Units

↓

Peptide
Type

NS

↓
NS

S

NS

Summary of statistically significant (p < 0.05) effects of polymer architecture on
performance in in vitro and ex vivo tests. The “↓” symbol indicates a decrease in the
response when the variable value is increased. Designations of “S” and “NS” indicate
effects that are specific (S) or not specific (NS) to the type of peptide unit conjugated to
the polymer. The “*” symbol indicates that the response only shows negative correlation
with the variable for the longest polymer chains.
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CHAPTER 7. INVESTIGATION OF INTERACTION BETWEEN CREKA AND
FIBRINOGEN

7.1.

Introduction
As has been demonstrated in the literature, the pentapeptide CREKA has

successfully been used to target nanoparticles to tumor sites based on the high levels of
fibrin present due to the well characterized leaky vasculature [168-173]. In addition, the
molecular configuration of this material has been characterized under a variety of
conditions [175-177]. The work described in Chapter 6 demonstrates that CREKA can
also be incorporated into polymers and used to interrupt the series of events that leads to
an extended fibrin gel matrix, promoting post surgical adhesion formation. To date,
however, no analysis of the interaction of this peptide with fibrin, or its precursor,
fibrinogen, has been reported.
Two complementary approaches were employed to begin the investigation of this
important interaction. First, the structure of fibrin gels grown from surfaces treated with a
series of polymeric materials was analyzed using a turbidity assay. The powerful optical
technique, circular dichroism (CD), was employed to probe the interaction of this peptide
with fibrinogen in the solution phase. While a much more detailed investigation of this
interaction is warranted, these two studies represent a critical first step in developing an
understanding of the nature of these interactions.
7.2.

Materials and Methods
For the structural analysis if fibrin, all of the materials listed in Table 4-2 were

employed. Circular dichroism was carried out with the free targeting peptide (CREKA)
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and the polymer conjugate deemed to have the best overall performance from previous
experiments (P3-H). All materials were prepared as previously described.
7.2.1.

Analysis of Fibrin Structure using UV-Visible Turbidity Assay
In order to investigate the structure of fibrin gels grown from the surface of

existing fibrin substrates under a variety of conditions, a microplate based turbidity
analysis was performed [224-225].
7.2.1.1.

Preparation of Fibrin Gel Substrate
A Costar high binding 96-Well EIA/RIA plate was used to maximize the strength

of interaction between the fibrin gel and the microplate. In order to create a stable gel on
the surface, fibrinogen (50 µL, 2.0 mg/mL), thrombin (20 µL, 2.5 U/mL), and calcium
chloride (10 µL, 100 mM) were added to each well. The resulting gel was allowed to cure
for 5 hours at room temperature. Each well was then rinsed twice with 200 µL TBS, and
care was taken to avoid removing the fibrin gel from the surface. A solution of each
material under investigation (50 µL, 0.10 mg/mL in TBS, n = 4) was added to the wells.
7.2.1.2.

Assessment of Fibrin Gel Structure
After treating each gel with the material under investigation, 150 µL of fibrinogen

(0.5 mg/mL in TBS) was added to each well. A partial UV-visible spectrum (350 – 500
nm) was collected for each well using the CaryWin UV UV-visible spectrophotometer.
After 90 minutes, a second UV-visible spectrum was collected. The turbidity of the
additional fibrin gel formed during the intervening 90 minutes was determined by
subtracting the initial reading from the final reading at each wavelength.
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Previously published studies have shown that it is possible to relate the turbidity
of the resulting gel to the structure of its composite fibers [223, 230-233]. Turbidity (τ)
can be calculated from the measured absorbance (Abs) value and the path length (b):

τ=

ln (10)∗Abs

(7-1).

b

As shown in Appendix A, this value can be related to the
fibrils by Equation (7-2):

τ=

6.52×10 −27
λ3

∙μ

mass

length

ratio (µ) of the fibrin

(7-2).

6.52×10 −27

As indicated by this expression, a plot of τ versus �

λ3

� should yield a straight line

with a slope of µ. Assuming an average well diameter of 0.661 mm, a 150 µL gel results

in a path length of 0.437 cm. Equation (7-2) can be employed, and a plot of τ versus
6.52×10 −27
𝜆𝜆 3

will yield a straight line with a slope equal to the ratio of mass to length ratio of
Da

the fibrin fibrils (µ) in �cm � to relate the turbidity of the gel to its structure.
7.2.2.

Circular Dichroism of Fibrinogen with Free Peptide and with Targeted
Polymeric Adhesion Barrier
Circular dichroism (CD) is a powerful optical technique often employed to

investigate the structure of proteins in solution and to probe the interaction of materials
with these proteins. Briefly, a sample of the material of interest is dissolved in a solvent
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and irradiated alternately with circularly polarized light with opposite polarities. Since
proteins fold into chiral structures, they interact differently with these two polarized
beams. The absorbed light is measured as a function of wavelength for each beam, and
the difference between these absorption values is used to study the structure of the
analyte. Numerous articles and books have been written describing the underlying
physics of the technique [234-237]. Other manuscripts offer guidance on the
experimental and analytical aspects of CD measurement [238]. Because of the nature of
the technique, it is necessary that the protein of interest be dissolved in a UV transparent
solvent. As a result, direct investigation of the insoluble fibrin molecule is impossible;
rather, it is customary to investigate interactions between ligands and fibrinogen and then
to apply these results to fibrin [239-241]. In this work, we employ this technique to study
the interaction between targeting peptides and solution phase fibrinogen.
7.2.2.1.

Preparation of Solutions for CD Measurements
Prior to preparing solutions, PBS was filtered with a 0.22 µm syringe filter.

Solutions of fibrinogen (0.1 to 200 µg/mL), CREKA (100 µg/mL), and P3-H (100
µg/mL) were prepared in this PBS buffer solution. These solutions were combined in the
appropriate ratios and diluted with PBS to prepare the samples shown in Table 7-1. All
samples were prepared fresh on the day of the experiment to minimize degradation of the
proteins in solution.
7.2.2.2.

Circular Dichroism Measurement
All CD measurements were performed at 37

o

C using the Jasco J-810

Spectropolarimeter controlled by the Jasco Spectral Measurement software. Spectra were
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collected from 320 to 200 nm. Each measurement is the average of four acquisitions
collected in a 1.0 mm quartz cuvette, and each sample was measured three times. In order
to avoid contamination between samples, the cuvette was cleaned with 1M nitric acid,
rinsed with copious amounts of DI water and ethanol, and dried with acetone between
samples. Analysis of blank PBS samples confirmed that this cleaning procedure removed
all traced of the sample from the cuvette.
7.2.2.3.

CD Data Analysis
In order to estimate the content of α -helical and β -sheet secondary structure in the

fibrinogen, each spectrum was analyzed using the K2D2 neural network deconvolution
algorithm [242-244]. This algorithm, accessible via an online interface, uses a neural
network to assess the structure of proteins in aqueous solution. By comparing the
observed CD spectrum with a database of 43 proteins with known structures, the K2D2
network can effectively estimate the α -helical and β -sheet content in the sample.
7.3.

Results

7.3.2.

Fibrin Structure
As previously described, the structure of the fibrils within a fibrin gel can be

probed by analyzing the turbidity of the gel as a function of wavelength. As shown in
6.52×10 −27

Figure 7-1, a plot of τ versus �

𝜆𝜆 3

�, yields a straight line, in good agreement with

theory. Using a linear least squares analysis in Excel, data for each well was analyzed.

The results of this analysis, shown in Figure 7-2 – Figure 7-4, summarize these results
for the materials tested. The control, with no polymer addition, yields a value of
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2.56 × 1012 ± 1.7 × 1011

Da

cm

and is shown on the figures as a horizontal line for

reference. Only EPC exhibited a statistical difference from the TBS control.
The residual plots for µ are shown in Figure 7-5. With the possible exception of 1
outlier, the normal probability plot is linear and the residuals are normally distributed.
The main effects plots, shown in Figure 7-6, indicate mass/length ratio is not affected by
the polymer chain length, the number of PEG chains, or the number of peptide units. The
value of µ decreases with increasing PEG chain length . No clear difference is observed
as a function of peptide type.
7.3.3.

CD Analysis
Representative CD spectra for the samples tested are shown in Figure 7-7. These

spectra indicate a change in secondary protein structure with the addition of either
CREKA or polymer. The intensity of the peak at 210 nm decreases with increasing
CREKA concentration; the effect of the polymer (100 µg/mL) is approximately
equivalent to the effect of 0.2 µg/mL of CREKA.
Circular dichroism measurements of solution phase fibrinogen in the absence of
targeting peptides indicate 32.5 ± 7.0 percent α -helical content and 20.4 ± 5.8 percent β sheet content. These results are in good agreement with previously published structural
data (35 – 42 percent α -helix, 20 – 25 percent β -sheet) and validate the accuracy of the
subsequent CD measurements [245-246]. As shown in Table 7-1, the addition of
CREKA or CAERK to the fibrinogen solution does not result in a significant change in
the α -helical content. The addition of CREKA at 0.20 and 1.0 µg/mL causes a decrease in
the β -sheet content from 20.4 ± 5.8 percent to approximately 12.4 ± 1.2 percent and 12.5
± 1.5 percent, respectively. A dose dependant decrease in β -sheet content was observed
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with the scramble peptide. The addition of 0.20 µg/mL CAERK results in a β -sheet
content of 16.0 ± 4.5 percent, while the sample with 1.0 µg/mL CAERK exhibited 10.2 ±
0.2 percent β -sheet content. The addition of 1.0 µg/mL P3-H to the fibrinogen solution
caused no decrease in α -helical content but did result in a decrease in β -sheet content to
12.6 percent.
7.4.

Discussion
As indicated by the data in this section, the materials tested in these studies had a

significant effect on the structure of fibrin gels propagated from an existing fibrin surface.
Although the individual comparisons reported in Figure 7-2 – Figure 7-4 fail to reveal a
strong significant difference among the samples, ANOVA analysis conducted on the
entire data set of polymer samples did reveal several important, statistically significant,
trends.
The effect of PEG chain length, indicating that longer PEG chains result in a
decrease in the mass/length ratio for the fibrin fibrils, suggests that longer PEG chains are
effective at inhibiting the deposition of fibrinogen to growing fibrin fibrils. As has been
discussed in Chapter 6, this result is in good agreement with previously published
studies, where the length of PEG chain is an important factor in the ability to suppress
protein adsorption. Surprisingly, the number of PEG chains does not appear to impact the
structure of the growing fibrin fibrils. This indicates that the steric effect of PEG chains
on adjacent monomer units in the polymer fails to result in enhanced protection against
protein deposition. It is possible that, in the environment tested, all of the PEG chains
form a fully hydrated hydrophilic core. While it was impossible to determine the number
of polymer chains adsorbed to the growing fibrin fibril, it is likely that a larger number of
150

low PEG number polymer chains are able to adhere to the surface. As a result, the total
number of PEG chains on the surface may be equivalent despite the difference in
molecular architecture.
The somewhat surprising observation that polymer chain length does not affect
the resulting fibrin structure may also be explained if it is assumed that the surface of the
fibrin fibrils is saturated with polymer. Although the longer polymer chains occupy a
larger surface area, the presence of additional polymer chains results in an equivalent
effect on the polymerized protein structure.
Although the trend in protein structure that results from changing the peptide is
ambiguous, it does appear that the presence of either CREKA or CAERK in the polymer
structure results in an increase in the specific mass of the fibrils. This is confirmed by the
clear trend observed that increasing the level of peptide conjugation increases the
measured value of µ. Two mechanisms may be responsible for this trend. If the presence
of the peptide simply increases the affinity for the polymers to the fibrin fibril surface, it
is conceivable that the observed increase simply results from the accumulation of
polymer around the fibrin core. Another potential explanation for this observation is that
the peptides on the polymer chain enhance the deposition of fibrin around these growing
fibrils by increasing the interacting with the solution phase protein and the growing fibril.
Without additional structural information about the structure of the fibrin generated in
these experiments, it is impossible to distinguish between these two potentialities;
however, since is appears likely that the surfaces are completely saturated with polymer,
the second explanation appears to be more likely.
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The observations made with circular dichroism can be used to begin to explain the
interaction of CREKA with fibrin and its precursor, fibrinogen. The fibrinogen solution
employed was prepared at a concentration of 100 µg/mL, or 0.29 µM. The peptide was
employed at concentrations of 0.33 and 1.7 µM. Since CD of the free peptide did not
reveal any secondary structure, all structural changes in the protein/peptide mixture were
attributed to alterations in the conformation of fibrinogen.
These preliminary circular dichroism measurements revealed what appears to be a
strong interaction between the peptide ligands and the fibrinogen molecule. The native
protein structure, which is in good agreement with previously published studies, showed
a large degree of change when incubated with the targeting peptides [245-249]. At either
a low (1.1:1) or high (5.6:1) peptide/protein ratio, the CREKA causes a similar
conformational change. The scramble, on the other hand, shows less change at the lower
concentration. This result indicates that, while CAERK binds to fibrinogen, it does so
with a much lower affinity than CREKA. In addition, since the CD data shows no change
in the α -helical content in the protein, it can be concluded that the binding site(s) for the
two peptides all reside in the β -sheet domains of the protein. The fact that no additional
conformational change is observed with greater than a 1.1:1 ratio of peptide to protein
suggests that each fibrinogen molecule contains only one peptide binding site. Although
these observations have a high degree of variability and do not provide sufficient detail to
discern the precise nature of the interaction between CREKA and fibrinogen, the large
conformational change suggests that CREKA interacts strongly with solution phase
fibrinogen.
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7.5.

Conclusion
The materials tested for use as prophylactic treatments for post surgical adhesion

prevention demonstrate the ability to bind to growing fibrin fibrils and to affect the
structure of the resulting structures. As anticipated, the observed trends indicate that PEG
chain length and degree of peptide conjugation are the most important factors in the
performance of the materials. The unanticipated results that the number of PEG chains
conjugated to the polymer and the overall polymer length are not important factors in
modifying the structure of the fibrin fibrils is likely attributable to the existence of a high
density of polymer chains bound to the protein surface. Circular dichroism measurements
of fibrinogen with free peptide and with peptide-conjugated polymer demonstrate strong
interactions with fibrinogen. While the CAERK scramble, used as a control, does bind to
the solution phase protein, it exhibits a much lower affinity for the protein than CREKA.
This finding confirms the ability of CREKA to serve as a useful moiety for targeting
polymers to fibrinogen and fibrin, but suggests that other peptide groups may also be
useful in controlling the affinity of the polymeric biomaterials for damaged tissues.
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Turbidity analysis.
A plot of turbidity (τ) versus �
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Figure 7-2

Mass/length ratio from turbidity analysis (controls and PMAA polymers).
Values (M ± SE) and statistical significance are given: 99% compared to
no polymer (b) and 95% compared to EPC (g).
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Figure 7-3

Mass/length ratio from turbidity Analysis (long PEG chain polymers).
Values (M ± SE) are given. No statistical significance was observed.
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Figure 7-4

Mass/Length Ratio from Turbidity Analysis (short PEG chain polymers).
Values (M ± SE) are given. No statistical significance was observed.
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Residual plots for fibrin mass/length ratio (µ).
The validity of the general linear model used for the ANOVA for the
mass
fibrin length ratio is confirmed by the residual plots. Three outliers are

observed for P1-L, P3-L, and P4-L. With the exception of these three
outliers, the linearity of the normal probability plot and random
distribution observed in the standardized residual plots indicate a lack of
bias in the model fit. The histogram of standardized residuals indicates a
normal distribution of residuals. In addition, the vast majority of the
residuals are within the expected range of ± 2 standard deviations. The
three outliers with standardized residuals above 3 arise from polymers
with the lowest level of CREKA conjugation.
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Main Effects Plot for µ
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Main effects plots for fibrin mass/length ratio (µ).
mass
The main effects plots for the length ratio for fibrin provide insight into the

importance of the various aspects of polymer architecture that were
investigated. No statistically significant dependence was observed for
polymer chain length, the number of PEG units, or the number of peptide
units. Increases in PEG chain length result in a decrease in the observed
value for µ. The impact of peptide type is unclear; however, the presence
of peptide units in the polymer appears to result in a larger value for µ.
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Circular dichroism measurements.
A comparison of CD spectra for fibrinogen (F), fibrinogen with 0.20
µg/mL CREKA (F+C (L)), fibrinogen with 1.0 µg/mL CREKA (F+C (H)),
and fibrinogen with 100 µg/mL P3-H (F+P). The peak at 210 nm
decreases with increasing CREKA; a similar level of decrease is observed
with the polymer as with the lower level of CREKA. Both of these peaks
CREKA
correspond to a fibrinogen ratio of approximately 1:1.
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Table 7-1

Results of Circular Dichroism Measurement

Sample

Description

Molar Ratio of
Peptide to
Fibrinogen

α -Helix Content
(Percent)
(M ± SE)

β -Sheet Content
(Percent)
(M ± SE)

F

100 µg/mL Fibrinogen in PBS

0

32.5 ± 7.0

20.4 ± 5.8

F + C (L)

100 µg/mL Fibrinogen + 0.20
µg/mL CREKA in PBS

1.1

34.1 ± 2.5

12.4 ± 1.2

F + S (L)

100 µg/mL Fibrinogen + 0.20
µg/mL CAERK in PBS

1.1

35.3 ± 5.3

16.0 ± 4.5

F + C (H)

100 µg/mL Fibrinogen + 1.0
µg/mL CREKA in PBS

5.6

35.1 ± 3.8

12.5 ± 1.5

F + S (H)

100 µg/mL Fibrinogen + 1.0
µg/mL CAERK in PBS

5.6

39.8 ± 0.4

10.2 ± 0.2

F+P*

100 µg/mL Fibrinogen + 1.0
µg/mL P3-H in PBS

1.0

33.0

12.6

*n=1
Summary of solutions used for circular dichroism (CD) investigation of fibrinogen
interactions. Each peptide was studied at 1.1:1 and 5.6:1 molar ratios to fibrinogen.
CREKA conjugated polymer was studied at a concentration that corresponds to 1 peptide
unit per protein molecule. With the exception of the polymer (n = 1), each value
represents the average of 3 – 4 independently prepared samples.

Copyright © John M. Medley 2010
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CHAPTER 8. CONCLUSIONS AND FUTURE STUDIES

In this research, a rational approach for the development of a series of novel
biomaterials for the prevention of post surgical adhesions has been employed. Starting
with a thorough understanding of the biochemistry and pathology of PSA formation,
these materials were developed specifically to meet this significant critical need. Robust
methodology to synthesize and characterize functionalized block and statistical
copolymers with precisely controlled molecular architecture has been developed. Initial
studies, focused on understanding the interaction of non-targeted polymers with
positively charged model surfaces, verified the viability of this approach and provided a
critical basis for the development of materials. Subsequent investigations of targeted
polymers led to an understanding of the relationship between the molecular architecture
and performance in a number of in vitro tests. The ability of these materials to interact
with fibrin as a marker of tissue damage and to reduce the propagation of the fibrin gel
matrix can be modulated by controlling the molecular architecture of the polymers.
Finally, the results of these experiments were employed to select materials for subsequent
in vivo experiments to assess their ability to prevent PSA formation in a rabbit model.
The power of this ground up approach to biomaterial development has been
validated. The promising preliminary results obtained in these experiments indicate the
need for additional studies, including the following:
•

The structure-property relationships that have been determined should be
employed to design and synthesize additional polymers for testing.

•

Investigation of biocompatibility.
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− Efforts to investigate biocompatibility should begin with an assessment of
the dose-dependent cytotoxicity of the materials, including the polymers
of interest and the targeting peptides. These studies should include
multiple cell types, as these materials will be in contact with many types
of cells in vivo.
− Additional biocompatibility tests should include histological investigation
of the tissues in close proximity to the materials, Ames testing, and LD50
testing.
•

The fibrin and fibrinogen binding studies that were conducted indicated a strong
interaction between CREKA and fibrinogen. Additional binding studies are
warranted in order to develop a better understanding of these interactions.
− CD can be used to determine the stoichiometry of the interaction between
the protein and peptide.
− Complementary techniques, including ITC and SPR, could be used to
investigate

the

kinetics

and

thermodynamics

of

protein-peptide

interactions.
− Additional studies should be conducted to ascertain the precise location of
the peptide binding sites in fibrinogen.
•

The effect of these materials on fibrin formation has been investigated. In order to
develop a better understanding of how these materials affect the fibrin gel matrix
formation, their impact on the rate of fibrinolysis should be evaluated in vitro.

•

Animal studies are needed to assess the in vivo performance of these materials
compared to existing PSA prevention technologies.
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•

Stability and biodistribution studies.
− Degradation of the polymers in vitro should be investigated to assess their
chemical stability.
− In vivo degradation should be investigated, and the biodistribution of the
polymer and degradation products should be studied in order to assess the
likelihood of adverse biological reactions.
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APPENDIX A. DERIVATION OF RELATIONSHIP BETWEEN FIBRIN
STRUCTURE AND TURBIDITY

This derivation, originally reported by Carr and Hermans, has been included for
clarity. Additional details, including the physical justification for the assumptions
included in the derivation can be found in the literature [230-233].

Turbidity is defined as the total amount of light scattered by a sample.
Mathematically, this is expressed as Equation A-1:

π

i

τ = ∫0 2 πd �Iθ � sinθ dθ
0

(A-1),

where τ is the turbidity, d is the distance from the sample to the detector, iθ is the intensity
of scattered light detected at angle θ , and I0 is the intensity of the intensity of the incident
beam. The ratio of the scattered light to the incident light is described by Equation A-2:

i

�Iθ � =
0

R θ �1+co s 2 θ�
d2

(A-2),

where Rθ is the Rayleigh scattering ratio and depends on the size and shape of the
particles causing the scattering. The value of the Rayleigh ratio can be calculated for rodshaped particles by Equation A-3:

Rθ =

Ck λμ

θ
2

4 η sin � �
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(A-3).

g

In Equation A-3, C is the concentration of particles in �cm 3 �, λ is the wavelength of the
mass

Dalton

incident light, µ is the �length � ratio of the particles in �
the solution, and k is a factor defined by Equation A-4:

k=

cm

dη 2
�
dc
4
Nλ

2 π2η2�

�, η is the refractive index of

(A-4).

dη

N in Equation A-4 represents Avogadro’s number, while � dc � represents the refractive

index increment of the solute. Substituting Equations A-2 and A-3 into Equation A-1
yields the following expression for turbidity:

πCk λμ

τ=�

2η

π �1+co s 2 θ�(sin θ)

� ∫0

θ
2

sin � �

dθ

(A-5).

Integration of Equation A-5 yields Equation A-6:

44 πCk λμ

τ=�

15 η

�

(A-6).

Substituting Equation A-4 into this expression yields Equation A-7:

τ=

dη 2
� Cμ
dc
Nλ 3

88 π 3 η�
15
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(A-7).

dη

Values for � dc � and η can obtained from literature (0.18

𝑐𝑐𝑚𝑚 3
𝑔𝑔

and 1.333, respectively)

[230]. Substituting these values, and the fibrinogen concentration of 5.00 × 10−4

Equation A-7 simplifies to Equation A-8:

τ=

6.52×10−27
λ3

μ
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(A-8).

g

cm 3

,

LIST OF ABBREVIATIONS
ABCR
ACN
ANOVA
BSA
CAERK
CD
CMC
CREKA
DCC
DCU
DI
DMEM
DNA
EDTA
EPC
FGM
GPC
GTP
HA
HAc
HAx
HPLC
MA
MN
MTS
MW
NAEM
NHS
NMR
ORC
PAA
PAI-1
PBS
PD
PE
PEG
PEGMA
PEO
PLG
PLGA
PLL
PMAA
PMN
PS

Bis-(dimethylamino)methylsilane
Acetonitrile
Analysis of Variance
Bovine Serum Albumin
Cysteine-Alanine-Glutamic Acid-Arginine-Lysine
Circular Dichroism
Carboxymethylcellulose
Cysteine-Arginine-Glutamic Acid-Lysine-Alanine
N,N’-Dicyclohexylcarbodiimide
N,N’-Dicyclohexylurea
Deionized
Dubecco’s Modified Eagle Medium
Deoxyribonucleic Acid
Ethylenediaminetetraacetic acid
Egg Phosphatidylcholine
Fibrin Gel Matrix
Gel Permeation Chromatography
Group Transfer Polymerization
Hyaluronic Acid
Acetic Acid
Crosslinked Hyaluronic Acid
High Performance Liquid Chromatography
Methacrylic Acid
Number Average Molecular Weight
1-Methoxy-1-(trimethylsiloxy)-2-methyl-1-propene
Weight Average Molecular Weight
N-Aminoethylmaleimide Trifluoroacetic Acid
N-Hydroxysuccinimide
Nuclear Magnetic Resonance
Oxidized Regenerated Cellulose
Poly(acrylic acid)
Plasminogen Activator Inhibitor-1
Phosphate Buffered Saline
Polydispersity
Polyethylene
Poly(ethylene glycol)
Poly(ethylene glycol methacrylate)
Poly(ethylene oxide)
Poly(L-glutamate)
Poly(lactic-co-glycolic acid)
Poly(L-lysine)
Poly(methacrylic acid)
Polymorphoneutrophils
Polystyrene
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PSA
PTBMA
PTFE
PTSA
QCM
QCM
rt-PA
r.t.
RID
SAM
SD
SE
SPIO
TBABB
TBMA
TCP
TFA
THF
TMS
tPA
UV
VASE

Post Surgical Adhesion
Poly(t-butyl methacrylate)
Poly(tetraflouroethylene)
Para-Toluenesulfonic Acid
Quartz Crystal Microbalance
Quartz Crystal Microbalance with Dissipation
Recombinant Tissue Plasminogen Activator
Retention Time
Refractive Index Detector
Self-Assembled Monolayer
Standard Deviation
Standard Error
Superparamagnetic Iron Oxide
tert-Butylammonium bibenzoate
tert-Butylmethacrylic acid
Tissue Culture Polystyrene
Trifluoroacetic Acid
Tetrahydrofuran
Trimethylsilyl
Tissue Plasminogen Activator
Ultraviolet
Variable Angle Spectroscopic Ellipsometry
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